SUPERNUS PHARMACEUTICALS, INC. 10-K

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. Supernus Pharmaceuticals, Inc. Consolidated Financial Statements Reports of Independent Registered Public Accounting Firm (PCAOB ID 185 ) 103 Consolidated Balance Sheets 107 Consolidated Statements of Earnings (Loss) 108 Consolidated Statements of Comprehensive Earnings (Loss) 109 Consolidated Statements of Changes in Stockholders' Equity 110 Consolidated Statements of Cash Flows 111 Notes to Consolidated Financial Statements 112 102 Table of Contents Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors Supernus Pharmaceuticals, Inc.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Supernus Pharmaceuticals, Inc. and subsidiaries (the Company) as of December 31, 2025 and 2024, the related consolidated statements of earnings (loss), comprehensive earnings (loss), changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 2, 2026 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Accrued sales deductions related to product returns As disclosed in Notes 2 and 16 to the consolidated financial statements, the Company recorded accrued product returns of $37,800 (dollars in thousands) as of December 31, 2025. The related provision for product returns is reflected as a reduction of gross product sales, and is recorded at the time of sale when the customer takes title to the product. Sale of the Company’s products are not subject to a general right of return; however, the Company will accept return of expired product six months prior to and up to 12 months subsequent to the product’s expiry date for certain products. The Company's products have a shelf life of up to 48 months from date of manufacture. We identified the evaluation of accrued sales deductions related to Trokendi XR, Oxtellar XR and Qelbree product returns, and specifically the assessment of the expected long-term return rates, as a critical audit matter. The assessment of the expected long-term return rates included a comparison to actual returns experience and involved a high degree of auditor judgment due to the significant passage of time between product sale and the time at which the Company issues credit for expired product. 103 Table of Contents The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the accrued sales deductions process. This included a control over the expected long-term return rate assumptions used in estimating the accrued product returns. We assessed the Company's long-term return rate assumptions by evaluating the consistency of those assumptions with the trend of actual historical return rates. We compared prior period expected long-term return rate assumptions against actual return rates experience. /s/ KPMG LLP We have served as the Company's auditor since 2015. Baltimore, Maryland March 2, 2026 104 Table of Contents Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors Supernus Pharmaceuticals, Inc.: Opinion on Internal Control Over Financial Reporting We have audited Supernus Pharmaceuticals, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of earnings (loss), comprehensive earnings (loss), changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements), and our report dated March 2, 2026 expressed an unqualified opinion on those consolidated financial statements. The Company acquired Sage Therapeutics, Inc. during 2025, and management excluded from its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2025, Sage Therapeutics, Inc.’s internal control over financial reporting associated with 9% of total revenues and 7% of total assets included in the consolidated financial statements of the Company as of and for the year ended December 31, 2025. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Sage Therapeutics, Inc. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control Over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. 105 Table of Contents Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ KPMG LLP Baltimore, Maryland March 2, 2026 106 Table of Contents Supernus Pharmaceuticals, Inc. Consolidated Balance Sheets (in thousands, except share and per share data) December 31, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 128,448 $ 69,331 Marketable securities 180,222 384,281 Accounts receivable, net 187,802 142,077 Inventories, net 82,385 54,293 Prepaid expenses and other current assets 65,325 36,088 Total current assets 644,182 686,070 Restricted cash 1,450 — Property and equipment, net 10,531 11,545 Intangible assets, net 569,456 521,912 Goodwill 124,882 117,019 Deferred income tax assets, net 38,351 — Other assets 63,796 31,527 Total assets $ 1,452,648 $ 1,368,073 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued liabilities $ 107,800 $ 76,352 Accrued product returns and rebates 161,097 168,705 Contingent consideration, current portion 31,052 47,340 Other current liabilities 38,222 — Total current liabilities 338,171 292,397 Contingent consideration, long-term 206 — Operating lease liabilities, long-term 30,365 27,382 Deferred income tax liabilities, net — 4,961 Other liabilities 22,192 7,600 Total liabilities 390,934 332,340 Commitments and contingencies (Note 18) Stockholders' equity Common stock, $ 0.001 par value; 130,000,000 shares authorized; 57,457,462 and 55,743,095 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively 57 56 Additional paid-in capital 543,825 479,440 Accumulated other comprehensive loss, net of tax ( 44 ) ( 189 ) Retained earnings 517,876 556,426 Total stockholders' equity 1,061,714 1,035,733 Total liabilities and stockholders' equity $ 1,452,648 $ 1,368,073 See accompanying notes. 107 Table of Contents Supernus Pharmaceuticals, Inc. Consolidated Statements of Earnings (Loss) (in thousands, except share and per share data) Year Ended December 31, 2025 2024 2023 Revenues Net product sales $ 626,536 $ 637,696 $ 573,933 Collaboration revenue (ZURZUVAE) 52,996 — — Royalty, licensing, and other revenues 39,420 24,121 33,588 Total revenues 718,952 661,817 607,521 Costs and expenses Cost of revenues (a) 74,562 77,906 83,779 Research and development 106,235 108,796 91,593 Selling, general and administrative 485,563 321,582 336,361 Amortization of intangible assets 89,456 77,977 82,385 Intangible asset impairment charges — — 20,189 Contingent consideration loss (gain) 25,419 ( 6,110 ) ( 1,517 ) Total costs and expenses 781,235 580,151 612,790 Operating earnings (loss) ( 62,283 ) 81,666 ( 5,269 ) Other income (expense) Interest and other income, net 13,253 16,204 10,453 Interest expense — — ( 2,415 ) Total other income (expense), net 13,253 16,204 8,038 Earnings (loss) before income taxes ( 49,030 ) 97,870 2,769 Income tax expense (benefit) ( 10,480 ) 24,005 1,453 Net earnings (loss) $ ( 38,550 ) $ 73,865 $ 1,316 Earnings (Loss) per share Basic $ ( 0.68 ) $ 1.34 $ 0.02 Diluted $ ( 0.68 ) $ 1.32 $ 0.02 Weighted average shares outstanding Basic 56,451,136 55,100,063 54,536,281 Diluted 56,451,136 55,958,537 55,506,828 (a) Excludes amortization of intangible assets. See accompanying notes. 108 Table of Contents Supernus Pharmaceuticals, Inc. Consolidated Statements of Comprehensive Earnings (Loss) (in thousands) Year Ended December 31, 2025 2024 2023 Net earnings (loss) $ ( 38,550 ) $ 73,865 $ 1,316 Other comprehensive gain (loss) Unrealized gain (loss) on marketable securities, net of tax 145 404 2,617 Other comprehensive gain (loss) 145 404 2,617 Comprehensive earnings (loss) $ ( 38,405 ) $ 74,269 $ 3,933 See accompanying notes. 109 Table of Contents Supernus Pharmaceuticals, Inc. Consolidated Statements of Changes in Stockholders' Equity (in thousands, except share data) Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Earnings (Loss) Retained Earnings Total Stockholders' Equity Shares Amount Balance, December 31, 2022 54,253,796 $ 54 $ 408,115 $ ( 3,210 ) $ 481,245 $ 886,204 Share-based compensation expense related to employee stock purchase plan and share-based awards — — 26,759 — — 26,759 Issuance of common stock related to employee stock purchase plan and share-based awards 469,560 1 4,619 — — 4,620 Net earnings — — — — 1,316 1,316 Unrealized gain on marketable securities, net of tax — — — 2,617 — 2,617 Balance, December 31, 2023 54,723,356 55 439,493 ( 593 ) 482,561 921,516 Share-based compensation expense related to employee stock purchase plan and share-based awards — — 27,755 — — 27,755 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld 1,019,739 1 12,192 — — 12,193 Net earnings — — — — 73,865 73,865 Unrealized gain on marketable securities, net of tax — — — 404 — 404 Balance, December 31, 2024 55,743,095 56 479,440 ( 189 ) 556,426 1,035,733 Share-based compensation expense related to employee stock purchase plan and share-based awards — — 31,000 — — 31,000 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld 1,714,367 1 33,385 — — 33,386 Net loss — — — — ( 38,550 ) ( 38,550 ) Unrealized gain on marketable securities, net of tax — — — 145 — 145 Balance, December 31, 2025 57,457,462 $ 57 $ 543,825 $ ( 44 ) $ 517,876 $ 1,061,714 See accompanying notes. 110 Table of Contents Supernus Pharmaceuticals, Inc. Consolidated Statements of Cash Flows (in thousands) Year Ended December 31, 2025 2024 2023 Cash flows from operating activities Net earnings (loss) $ ( 38,550 ) $ 73,865 $ 1,316 Adjustments to reconcile net earnings (loss) to net cash provided by operating activities: Depreciation and amortization 91,563 80,414 84,859 Intangible asset impairment charges — — 20,189 Amortization of deferred financing costs and debt discount — — 532 Realized loss (gains) from sales of marketable securities 439 ( 9 ) — Amortization of premium/discount on marketable securities ( 1,529 ) 1,823 ( 122 ) Change in fair value of contingent consideration 25,419 ( 6,110 ) ( 1,517 ) Share-based compensation expense 33,051 27,755 26,759 Deferred income tax benefit 5,206 ( 20,136 ) ( 25,714 ) Inventory valuation write-down 1,926 8,876 8,023 Payment of contingent consideration ( 4,900 ) — — Noncash lease expense 7,980 5,452 6,503 Other noncash adjustments, net 1,885 2,073 ( 606 ) Changes in operating assets and liabilities: Accounts receivable ( 22,304 ) 2,078 18,765 Inventories ( 7,502 ) 15,806 6,110 Prepaid expenses and other assets ( 13,179 ) ( 19,352 ) ( 334 ) Accrued product returns and rebates ( 7,608 ) 14,431 2,609 Accounts payable and other liabilities ( 24,566 ) ( 15,015 ) ( 36,287 ) Net cash provided by operating activities 47,331 171,951 111,085 Cash flows from investing activities Acquisition of Sage, net of cash acquired ( 293,093 ) — — Purchases of marketable securities ( 475,941 ) ( 688,013 ) ( 101,621 ) Maturities of marketable securities 774,478 498,871 370,901 Purchases of property and equipment ( 1,338 ) ( 725 ) ( 551 ) Net cash provided by (used in) investing activities 4,106 ( 189,867 ) 268,729 Cash flows from financing activities Proceeds from Credit Line — — 93,000 Payments on Credit Line — — ( 93,000 ) Payment on convertible notes — — ( 402,500 ) Proceeds from issuance of common stock 37,616 14,908 6,610 Employee taxes paid related to net share settlement of equity awards ( 4,229 ) ( 2,715 ) ( 1,990 ) Payment of contingent consideration ( 24,257 ) — — Net cash provided by (used in) financing activities 9,130 12,193 ( 397,880 ) Net change in cash, cash equivalents, and restricted cash 60,567 ( 5,723 ) ( 18,066 ) Cash and cash equivalents at beginning of year 69,331 75,054 93,120 Cash, cash equivalents, and restricted cash at end of year $ 129,898 $ 69,331 $ 75,054 Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets Cash and cash equivalents $ 128,448 $ 69,331 $ 75,054 Restricted cash 1,450 — — Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 129,898 $ 69,331 $ 75,054 Supplemental cash flow information Cash paid for income taxes $ 16,051 $ 53,254 $ 36,602 Cash paid for interest on debt $ — $ — $ 1,946 See accompanying notes. 111 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements 1. Business Organization Supernus Pharmaceuticals, Inc. (the Company, see Consolidation in Note 2, Summary of Significant Accounting Policies ) was incorporated in Delaware and commenced operations in 2005. The Company is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders. The Company has nine commercial products: Qelbree ® , GOCOVRI ® , Oxtellar XR ® , APOKYN ® , Trokendi XR ® , XADAGO ® , MYOBLOC ® , ONAPGO TM , (formerly known as SPN-830), and ZURZUVAE ® (see Note 3, Sage Acquisition ). In February 2025, the FDA approved ONAPGO (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. ONAPGO was launched in April 2025. In September 2025, the Federal Drug Administration (FDA) withdrew the New Drug Application (NDA) for OSMOLEX ER. Acquisition of Sage Therapeutics, Inc. and Reorganization On June 13, 2025, the Company entered into an Agreement and Plan of Merger (Merger Agreement) to acquire Sage Therapeutics, Inc. (Sage). The acquisition closed on July 31, 2025. Sage was a pharmaceutical company with a portfolio of product candidates to address a range of neurological diseases and a commercial product to treat PPD. Sage's commercialized product, ZURZUVAE ® (zuranolone) capsules, is the first and only FDA-approved oral medicine indicated for the treatment of postpartum depression in adults. As of July 31, 2025, Sage became a wholly-owned subsidiary of the Company. With the acquisition of Sage, the Company acquired the rights to further develop and market ZURZUVAE. Through a collaboration agreement with Biogen MA Inc. (BIMA) and Biogen International GmbH (together with BIMA, Biogen), the Company reports collaboration revenue that is 50 % of total net revenue recorded by Biogen for ZURZUVAE in the United States (U.S.). See Note 3, Sage Acquisition , for further details on the acquisition and Note 15, Collaboration Agreements, for further details on the collaboration agreement with Biogen. Following the Sage Acquisition, during the third quarter of 2025, Sage Therapeutics, Inc. was reorganized into Sage Therapeutics, LLC. 2. Summary of Significant Accounting Policies Basis of Presentation The Company's consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). The Company, which is primarily located in the United States (U.S.), operates in one operating segment. Consolidation The Company's consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly-owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. All material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive 112 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) benefits from, the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions. Use of Estimates The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates. Cash and Cash Equivalents The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less to be cash equivalents. Accounts Receivable, Net The Company's trade accounts receivable arise from product sales and represents amounts due from its customers. In addition, the Company records accounts receivable arising from its collaboration and licensing agreements. The Company monitors the financial performance and credit worthiness of its counterparties so that it can properly assess and respond to changes in their credit profile. The Company provides allowances against receivables for estimated losses, if any, that may result from a counterparty's inability to pay. Amounts determined to be uncollectible are written-off against the allowance. Marketable Securities Marketable securities consist of investments in U.S. Treasury bills and notes; bank certificates of deposit; various U.S. government agency debt securities; corporate and municipal debt securities. The Company places all investments with governmental, industrial, or financial institutions whose debt is rated as investment grade. The Company's investments are classified as available-for-sale and are carried at fair value. The Company classifies all available-for-sale marketable securities with maturities greater than one year from the balance sheet date as non-current assets. Any unrealized holding gains or losses on debt securities, including their tax effect, are reported as components of Other comprehensive gain (loss) in the consolidated statement of comprehensive earnings (loss). Realized gains and losses, included in Interest and other income, net in the consolidated statement of earnings (loss), are determined using the specific identification method for determining the cost of securities sold. Declines in fair value below amortized cost related to credit losses (i.e., impairment due to credit losses) are included in the consolidated statement of earnings (loss), with a corresponding allowance established. If the estimate of expected credit losses decreases in subsequent periods, the Company will reverse the credit losses through current period earnings and adjust the allowance accordingly. 113 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Business Combinations and Contingent Consideration The Company determines whether an acquisition should be accounted for as a business combination or as an asset acquisition. If the acquired set of activities and assets does not meet the definition of a business, as defined by U.S. GAAP, the transaction is accounted for as an asset acquisition. In an asset acquisition, any acquired research and development that does not have an alternative future use is charged to expense as of the acquisition date, and no goodwill is recorded. If the acquired set of activities and assets meets the definition of a business, the Company applies the acquisition method of accounting and accounts for the transaction as a business combination. In a business combination, assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets, if applicable, is recorded as goodwill. In a business combination, the operating results of the acquired business are included in the Company's consolidated statement of earnings (loss), beginning on the effective acquisition date. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. Significant judgment is involved in the determination of the fair value assigned to assets acquired and liabilities assumed in a business combination, as well as the estimated useful lives of assets. These estimates can materially affect the Company's consolidated results of operations and financial position. The fair value of intangible assets are determined using information available as of the acquisition date and are based on estimates and assumptions that are deemed reasonable by management. Significant estimates and assumptions include but are not limited to: the probability of regulatory approval, revenue growth, and appropriate discount rate. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed as of the acquisition date, estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to the Company's consolidated statements of earnings (loss) in the period that these adjustments are identified. Additional information regarding the Company's recent business combination is included in Note 3, Sage Acquisition . Contingent Consideration Business combinations often include provisions for additional consideration to be transferred to former shareholders based upon the achievement of certain milestones, referred to as contingent consideration. Contingent consideration from product development milestones and sales-based milestone payments on future product sales are included in the purchase price for business combinations. The fair value of the contingent consideration liability is determined as of the acquisition date using estimated or forecasted inputs. These inputs include the estimated amount and timing of projected revenues, probability and timing of milestone achievement, probability of achieving regulatory approval, revenue volatility, and the estimated discount rates and risk-free rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period prior to the resolution of the contingency, the contingent consideration liability is remeasured at current fair value, with changes recorded in earnings in the period of remeasurement. The determination of the initial and subsequent fair value of the contingent consideration liability may require significant judgment by management. Changes in any of the inputs not related to facts and circumstances existing as of the acquisition date may result in a significant fair value adjustment, which can impact the results of operations in the period in which the adjustment is made. Changes that are not measurement period adjustments are reported on the consolidated statement of earnings (loss) in Contingent consideration loss (gain) . Additional information regarding contingent consideration, including the contingent consideration arrangement resulting from the Company's recent business combination, is included in Note 7, Contingent Consideration. 114 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents, marketable securities, and accounts receivable. The counterparties are various corporations, governmental institutions, and financial institutions of high credit standing. Substantially all of the Company's cash, cash equivalents, and marketable securities are maintained in U.S. Treasury bills and notes; bank certificates of deposit; various U.S. governmental agency debt securities; and corporate and municipal debt securities. The Company places all investments with governmental, industrial, or financial institutions whose debt is rated as investment grade. Deposits held with banks may exceed the amount of governmental insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and therefore, these bear minimal default risk. The following table shows the percentage of the Company's sales made to customers representing more than 10% of the Company's total gross product sales, and the percentage of the Company's accounts receivables, net from each: Percentage of Gross Product Sales Percentage of Accounts Receivable, net 2025 2024 2023 2025 2024 Customer A 27 % 28 % 28 % 35 % 40 % Customer B 24 % 24 % 23 % 30 % 28 % Customer C 25 % 25 % 25 % 17 % 16 % Customer D 14 % 13 % 12 % 9 % 8 % 90 % 90 % 88 % 91 % 92 % Refer to Note 4, Disaggregated Revenues , for the concentration of net product sales. Inventories Inventories are recorded at the lower of cost or net realizable value, and include materials, labor, direct costs and indirect costs. These are valued using the first-in, first-out method. Prior to the initial date that regulatory approval is received for a product candidate of the Company, costs related to the production of inventory are recorded as research and development expense on the Company’s consolidated statements of earnings (loss) in the period incurred. Raw and intermediate materials that may be utilized for either research and development or commercial purposes, after approval of the product by the FDA, are classified as inventory. Amounts in inventory that are used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an “alternative future use” as defined in authoritative guidance. The Company has acquired inventory from the Sage Acquisition, and recorded a corresponding liability related to this inventory, which represents the consideration paid by a customer to the Company for inventory cost as part of the Collaboration Agreement. The Company periodically reviews inventory and records write-downs for any excess, expired and obsolete inventory, and for inventory that has a cost basis in excess of its expected net realizable value based on estimates of product demand, production requirements, market conditions, regulatory requirements and spoilage. The write-down to net realizable value is recorded in the period in which impairment is identified and is recorded as a component of Cost of revenues in the consolidated statement of earnings (loss). The Company expects to use the inventory that is classified within current assets on its consolidated balance sheet over its operating cycle. Inventory that is not expected to be used over the Company’s operating cycle is classified as a non-current asset and is included in Other assets in the consolidated balance sheet. 115 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Property and Equipment Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following useful lives: Computer equipment 3 years - 5 years Software 3 years - 5 years Lab equipment and furniture 5 years - 10 years Leasehold improvements Shorter of lease term or useful life Intangible Assets Intangible assets consist of definite-lived intangible assets, including: acquired developed technology and product rights intangible, and patent defense costs. They also consist of indefinite-lived intangible assets, such as acquired in-process research and development (IPR&D) and goodwill. Patent defense costs are deferred legal fees that have been incurred in connection with legal proceedings related to the defense of patents for Oxtellar XR and Trokendi XR. Patent defense costs are charged to expense in the event of an unsuccessful outcome of the litigation. Definite-lived intangible assets (including acquired developed technology and product rights) are carried at acquisition date fair value less accumulated amortization, with amortization calculated on a straight line basis over the estimated useful lives. The Company evaluates the estimated remaining useful lives of its intangible assets annually or when events or changes in circumstances warrant a revision to the remaining periods of amortization. Acquired IPR&D in a business combination is considered an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon successful completion of the project, the Company will determine the then-useful life of the intangible asset. This is generally determined as the period over which the substantial majority of the cash flows are expected to be generated. The capitalized amount is then amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. During the period prior to completion or abandonment, the IPR&D asset is not amortized but tested for impairment on an annual basis or when potential indicators of impairment are identified. Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment, operating lease assets, and definite-lived intangible assets. The Company assesses the recoverability of its long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset would be compared to the carrying value of the asset to determine whether the asset's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made. Goodwill and Goodwill Impairment Assessment Goodwill is calculated as the excess of the consideration paid consequent to completing the acquisition, compared to the net assets recognized in a business combination and is recognized at acquisition date. Goodwill represents the future economic benefits from the other acquired assets that could not be individually identified and separately quantified. The Company evaluates goodwill for possible impairment at least annually (during the fourth quarter of each fiscal year), or more often, if and when events and circumstances indicate that goodwill may be impaired. The annual evaluation is generally 116 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) based on an assessment of qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. This includes but is not limited to, significant adverse changes in the business climate, market conditions, or other events that indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the Company is unable to conclude whether the goodwill is not impaired after considering the totality of events and circumstances during its qualitative assessment, the Company performs a quantitative assessment by estimating the fair value of the reporting unit and comparing the fair value to the carrying amount. Evaluating for impairment requires judgment, including identifying reporting units and estimating future cash flows. The Company estimates the fair values of its reporting unit using discounted cash flow models or other valuation models, such as comparative transactions or market multiples. If the carrying amount of the reporting unit exceeds its fair value, the Company writes down the goodwill to the estimated fair value, and an impairment loss equal to the difference is recognized in the consolidated statement of earnings (loss) in the period at which such determination is made. Revenue Recognition The Company determines revenue recognition for its contractual arrangements with customers based on the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the Company satisfies the relevant performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company does not adjust revenue for any financing effects in transactions where the Company expects the period between the transfer of the goods or services and collection to be less than one year. The Company has no contract assets as of December 31, 2025 or 2024. The Company has $ 3.1 million of contract liabilities as of December 31, 2025, and no contract liabilities as of December 31, 2024. Revenue from Product Sales The Company's customers are primarily pharmaceutical wholesalers, specialty pharmacies, and pharmaceutical distributors. Customers purchase product to fulfill orders from retail pharmacy chains and independent pharmacies of varying size and purchasing power. The Company recognizes gross product sales when its customers take control of its products, including title and ownership. Customer orders are generally fulfilled within a few days of order receipt, resulting in minimal order backlog. The Company recognizes revenue from product sales in an amount that reflects the consideration the Company expects to ultimately receive in exchange for those goods. Product sales are recorded net of various forms of variable consideration, including: provision for estimated rebates; provision for estimated future product returns; and an estimated provision for discounts. These are collectively considered sales deductions. Sales deductions are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of sale using the most likely value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal will not occur. Variability in the net transaction price for the Company's products arises primarily from the aforementioned sales deductions. Significant judgment is required in estimating certain sales deductions. In making these estimates, the Company considers: historical experience; product price increases; current contractual arrangements under applicable payor programs; unbilled claims; processing time lags for claims; inventory levels in the wholesale, specialty pharmacy, and retail distribution channel; and product life cycle. The Company adjusts its estimates of revenue either when the most likely amount of consideration it expects to receive changes, or when the consideration becomes fixed. If actual results in the future vary from its estimates, the Company adjusts its estimates in the period identified. These adjustments could materially affect net product sales and earnings in the period in which the adjustment(s) is recorded. 117 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Sales Deductions The Company records product sales net of rebates, returns and discounts. • Rebates - Rebates are discounts which the Company pays under either public sector or private sector health care programs. Rebates paid under public sector programs are generally mandated under law, whereas private sector rebates are generally contractually negotiated by the Company with managed care providers. Both types of rebates vary over time. Rebates are owed when the Company's customer dispenses the Company's product to a patient; i.e., filling a prescription. For each of its products, the Company bases its estimates of expected rebate claims on multiple factors, including: historical levels of deductions; contractual terms with managed care providers; actual and anticipated changes in product price; prospective changes in managed care fee for service contracts; prospective changes in co-payment assistance programs; and anticipated changes in program utilization rates; i.e., patient participation rates under each specific program. The Company records an estimated liability for rebates at the time the customer takes title to the product (i.e., at the time of sale to wholesalers/distributors). This liability is recorded as a reduction to gross product sales, and an increase in Accrued product returns and rebates. The liability is recorded as a component of current liabilities on the consolidated balance sheets. • Returns - Sales of the Company's products are not subject to a general right of return. A product that has been used to fill patient prescriptions is no longer subject to any right of return. However, the Company will accept a return of product that is damaged or defective when shipped from its third party fulfillment centers. The Company will also accept a return of expired product six months prior to and up to twelve months subsequent to the product's expiry date for certain products. Expired or defective returned product cannot be re-sold and is therefore destroyed. The Company records an estimated liability for product returns at the time the customer takes title to the product (i.e., at time of sale). The liability is reflected as a reduction to gross product sales, and an increase in Accrued product returns and rebates. This liability is recorded as a component of current liabilities on the consolidated balance sheets. The Company estimates the liability for returns primarily based on the actual returns experience for its commercial products. Because the Company's products have a shelf life up to forty-eight months from the date of manufacture, and because the Company accepts return of product up to twelve months post its expiry date, there is a time lag of several years between the time when the product is sold and the time when the Company may issue credit on the expired product. • Sales discounts - Distributors and wholesalers of the Company's pharmaceutical products are generally offered various forms of consideration, including allowances, service fees and prompt payment discounts, for distributing our products. Distributor and wholesaler allowances and service fees arise from contractual agreements and are estimated as a percentage of the price at which the Company sells product to them. In addition, distributors and wholesalers are offered a prompt pay discount for payment within a specified period. Prompt pay discounts are estimated as a percentage of the price at which the Company sells product. The Company accounts for these discounts at the time of sale as a reduction to gross product sales and Accounts receivable, net . Royalty, Licensing, Collaboration, and Other Revenues Royalty Revenues Royalty revenues include cash royalty amounts received from third parties pursuant to settlement agreements and agreements with collaboration partners for the right to use the Company's intellectual property as a functional license. These agreements may include sales-based royalties on the licensed intellectual property to which the royalties relate and milestone payments based on the level of sales (collectively, sales-based royalties). For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty revenues using the most likely amount method. Certain of the Company’s royalty revenues are recognized by the Company based on information supplied to the Company by its licensees and require estimates to be made. Sales-based royalties are recorded based on estimated net sales of the underlying product. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, which is generally within the following quarter. The difference between the Company’s actual and estimated royalty revenues has not been material to date. 118 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Historically, royalty revenues also included noncash royalty revenues for amounts earned pursuant to its royalty agreement with United Therapeutics Corporation (United Therapeutics) and was based on estimated product sales of Orenitram by United Therapeutics. During the second quarter of 2023, full ownership of the royalty rights has reverted back to the Company as the cumulative payment threshold has been reached (see Note 4, Disaggregated Revenues). There are no guaranteed amounts owed to the Company related to any of these royalty revenue agreements. License Revenues The Company's agreements with third parties generally involve the right to use the Company's intellectual property as a functional license. Certain agreements include an up-front license fee and ongoing milestone payments upon the achievement of specific events, and may also require minimum royalty payments based on in-country sales of products developed from the applicable intellectual property. In determining when to recognize the revenue under a collaboration agreement, the Company assesses whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. Generally, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Generally, milestone payments under the Company’s collaboration agreements with third parties are non-refundable. The Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. This can involve management's judgment that includes assessing factors that are outside of the Company's influence, such as: likelihood of regulatory success; availability of third party information; and expected duration of time until achievement of event. These factors are evaluated based on the specific facts and circumstances. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and would be included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience, the specific facts and circumstances, and the significance a third-party has on the outcome. Milestone payments that are not within the control of the Company, such as approval from regulatory authorities or where attainment of the specified event is dependent on the development activities of a third-party, are fully constrained and are not included in the transaction price until the period in which those regulatory approvals are obtained, or the specified event occurs due to the inherent uncertainty with the approval process. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied as noted below. Collaborative Arrangements At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification Topic 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of Accounting Standards Codification Topic 606, Revenue from Contract with Customers , (ASC 606). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method 119 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company performs the five-step model under ASC 606 as noted above to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements and presents the arrangement as R oyalty, licensing and other revenue or C ollaboration revenue (ZURZUVAE) in the consolidated statements of earnings (loss). For those elements of the arrangement that are accounted for pursuant to ASC 808, the Company evaluates the income statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. Payments or reimbursements that are the result of a collaborative relationship instead of a vendor-customer relationship are recorded as an increase to C ollaboration revenue (ZURZUVAE) , an increase to or reduction of Cost of revenues , R esearch and development expense , or S elling, general and administrative expense , depending on the nature of the activity. The Company applies ASC 808 and ASC 606 to the following collaboration agreements: • Biogen - The Company has a collaboration agreement with Biogen (Biogen Collaboration Agreement) for the co-commercialization of ZURZUVAE in the U.S. Since the acquisition of Sage, revenues from the Biogen Collaboration Agreement include the Company’s share of ZURZUVAE revenues as that element of the agreement is accounted for under ASC Topic 808. The Company reports as C ollaboration revenue (ZURZUVAE) its share of ZURZUVAE revenues, which is 50 % of total net revenue recorded by Biogen for ZURZUVAE in the U.S. The Company also identified the following promises in the Biogen Collaboration Agreement that were evaluated under the scope of ASC 606: delivery of (i) a co-exclusive license for SAGE-217 products in the U.S.; (ii) an exclusive license for SAGE-217 products outside of the United States other than Japan, the Republic of Korea, and Taiwan (Biogen Territory); (iii) commercial manufacturing supply of active pharmaceutical ingredient (API) and bulk drug product for SAGE-217 products in the Biogen Territory, and (iv) commercial manufacturing supply of API and bulk drug product for SAGE-217 in the U.S. The Company also evaluated whether certain options outlined within the Biogen Collaboration Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Biogen and therefore are not considered separate performance obligations within the Biogen Collaboration Agreement. The Company assessed the above promises at contract inception and determined that the co-exclusive license for SAGE-217 products in the U.S. is reflective of a vendor-customer relationship and therefore represent performance obligations within the scope of ASC 606. The co-exclusive license for SAGE-217 products in the U.S. is considered functional intellectual property and distinct from other promises under the contract. The exclusive license for SAGE-217 products in the Biogen Territory is considered a functional license that is distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the license on its own or together with other readily available resources. As the co-exclusive license in the U.S. and the exclusive license in the Biogen Territory are delivered at the same time, they are considered one performance obligation at contract inception. The commercial manufacturing supply of API and bulk drug product for SAGE-217 products for the Biogen Territory, as well as in the U.S., are considered distinct in the context of the Biogen Collaboration Agreement as Biogen can benefit from the manufacturing services together with the licenses transferred by the Company at the inception of the Biogen Collaboration Agreement. Therefore, each represents a separate performance obligation within a contract with a customer under the scope of ASC 606 at contract inception and is recorded in Royalty, licensing, and other revenues . • Shionogi - The Company also has a collaboration agreement with Shionogi & Co., Ltd. (Shionogi) (Shionogi Collaboration Agreement) whereby the Company is entitled to receive royalties and milestone payments upon achievement of certain milestones. The Shionogi Collaboration Agreement also includes arrangement for the supply of drug product for Shionogi’s clinical trials. The Company concluded that Shionogi meets the definition of a customer because the Company is delivering intellectual property and know-how rights for the zuranolone program in support of 120 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) territories in which the parties are not jointly sharing the risks and rewards. In addition, the Company determined that the Shionogi Collaboration Agreement met the requirements to be accounted for as a contract, including that it is probable that the Company will collect the consideration to which the Company is entitled in exchange for the goods or services that will be delivered to Shionogi. The Company assessed the promises at contract inception and determined that the license to zuranolone and supply of products to Shionogi are reflective of a vendor-customer relationship and therefore represent performance obligations within the scope of ASC 606. The Company determined that the performance obligations in the Shionogi Collaboration Agreement included the license to zuranolone and the supply of certain materials during the clinical development phase, which includes the supply of API. The performance obligation related to the license to zuranolone was determined to be distinct from other performance obligations and therefore was a separate performance obligation for which control was transferred upon signing, and is recorded in Royalty, licensing, and other revenues . The obligation to provide certain clinical materials, including API for use during the development period, was determined to be a separate performance obligation, and is recorded in Royalty, licensing, and other revenues . For additional information on the collaboration agreements with Biogen and Shionogi, as well as the Company's other collaboration arrangements, refer to Note 15, Collaboration Agreements . Cost of Revenues Costs of revenues includes primarily cost of materials; third-party manufacturing costs; freight and distribution costs; direct labor; cost of royalties; cost to write down inventory to net realizable value; manufacturing overhead costs, including quality control and assurance; and may also include period costs related to certain inventory manufacturing services. Fair value of inventories acquired through business combinations or asset acquisitions include an inventory step-up within the value of inventories. The inventory step-up value is amortized as the related inventory is sold, and included in Costs of revenues . Costs of revenues also includes our proportionate share of ZURZUVAE manufacturing costs under the Biogen Collaboration Agreement, (for additional information, refer to Note 15, Collaboration Agreements ). Research and Development Expenses Research and development expenditures are expensed as incurred. These expenses include: employee salaries, benefits, and share-based compensation; cost of contract research and development services provided by third parties; costs for preclinical and clinical studies; cost of acquiring or manufacturing clinical trial materials; regulatory costs; research facilities costs; depreciation expense and allocated occupancy expenses; and license fees and milestone payments related to in-licensed products and technologies. Acquired IPR&D assets that are used for research and development and have no future alternative use are expensed as incurred in research and development. The Company estimates preclinical and clinical trial expenses based on services performed pursuant to contracts with research institutions, clinical investigators, clinical research organizations (CROs), and other service providers that perform services on the Company's behalf. In recording service fees, the Company estimates the cost of those services performed on behalf of the Company during the current period and compares those costs with the cumulative expenses recorded and payments made for such services. As appropriate, the Company accrues additional expense for services that have been delivered or defers nonrefundable advance payments until the related services are performed. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts its accrued expenses, or its deferred advance payments, accordingly. If the Company subsequently determines that it no longer expects the services associated with a nonrefundable advance payment to be rendered, the remaining portion of that advance payment is charged to expense in the period in which such determination is made. 121 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Share-Based Compensation Stock Options The Company recognizes share-based compensation expense over the service period, using the straight-line method. Employee share-based compensation for stock options is determined using the Black-Scholes option-pricing model to compute the fair value of option grants as of their grant date. Forfeitures are accounted for as incurred. The Company uses the following assumptions for estimating the fair value of option grants: • Fair Value of Common Stock —The fair value of the common stock underlying the option grants is determined based on observable market prices of the Company's common stock. • Expected Volatility —Volatility is a measure of the amount by which the Company's share price has historically fluctuated or is expected to fluctuate on a daily basis and is expected to fluctuate (i.e., expected volatility) in the future. • Expected Dividend Yield —The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. The expected dividend yield is therefore zero . • Expected Term —This is the period of time during which options are expected to remain unexercised. The Company determines the expected term based on the historical exercise behavior of the stock option plan participants. Options have a maximum contractual term of ten years . • Risk-Free Interest Rate —This is the observed U.S. Treasury Note rate as of the week each option grant is issued, with a term that most closely resembles the expected term of the option. Restricted Stock Units (RSUs) Share-based compensation expense is recorded based on amortizing the fair market value of the RSU as of the date of the grant over the implied service period. RSUs granted to employees generally vest over four equivalent annual installments, starting on the first anniversary of the grant. RSUs granted to directors generally vest over a one year term. Forfeitures are accounted for as incurred. Performance Stock Units (PSUs) Performance-Based Awards Share-based compensation expense for performance-based awards is recognized based on amortizing the fair market value of the award as of the grant date over the periods during which the achievement of the performance target is probable . Performance-based awards require certain performance targets to be achieved in order for the award to vest . Vesting occurs on the date of achievement of the performance target. Forfeitures are accounted for as incurred. Market-Based Awards Share-based compensation expense for market-based awards is recognized on a straight-line basis over the requisite service period, regardless of whether the market condition has been satisfied. Market-based PSU awards vest upon the achievement of the performance target. Forfeitures are accounted for as incurred. The Company estimates the fair value of these awards as of the grant date using a Monte Carlo simulation that incorporates option-pricing inputs. This simulation covers the period from the grant date through the end of the derived requisite service period. Volatility as of the grant date is estimated based on historical daily volatility of the Company's common stock over a period of time, which is equivalent to the expected term of the award. The risk-free interest rate is based on the U.S. Treasury Note rate, as of the week, the award is issued, with a duration that most closely resembles the expected term of the award. 122 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Leases The Company determines if an arrangement is a lease considering whether there is an identified asset, and the contract conveys the right to control its use. Leases with an initial term of twelve months or less are not recorded on the balance sheet. Right-of-use (ROU) assets and lease liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The Company calculates the present value of future payments by using an estimated incremental borrowing rate, which approximates the rate at which the Company would borrow, on a secured basis and over a similar term. This rate is estimated based on information available at the commencement date of the lease and may differ for individual leases or portfolios of leased assets. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and lease liabilities. Lease expense for operating leases is recognized on a straight-line basis over the expected lease term and recognized as an operating cost. Some of the Company's leases include options to terminate prior to the end of the lease term or to extend the lease for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. The Company's lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes, or other costs. Variable lease costs are expensed as incurred on the consolidated statements of earnings (loss). The Company's lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. Advertising Expense Advertising expense includes the cost of promotional materials and activities, such as print materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred. The Company incurred approximately $ 96.1 million, $ 88.5 million, and $ 99.7 million in advertising expense for the years ended December 31, 2025, 2024, and 2023, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the consolidated statements of earnings (loss). Insurance Recoveries The Company has several policies with third-party insurers that provide for the recovery of certain costs incurred by the Company. The Company records its rights to insurance recoveries as a receivable when the respective costs are reimbursable under applicable insurance policies, it is probable that such costs will be reimbursed, and reimbursement can be reasonably estimated. As such, the Company estimates the percentage of costs that will be reimbursed by the insurance provider to determine the amount to record for the insurance recovery receivable. Insurance recoveries recognized in fiscal year 2025 and 2024 were recorded as a reduction to Selling, general and administrative expenses . The Company recorded approximately $ 10.3 million and $ 14.2 million of insurance recoveries during the years ended December 31, 2025 and 2024, respectively. There were no insurance recoveries during the year ended December 31, 2023. Insurance recovery receivable was $ 1.8 million and $ 4.0 million as of December 31, 2025 and December 31, 2024, respectively. Interest Expense Interest expense included the amortization of deferred financing costs and debt discount incurred by the Company in connection with the issuance of $ 402.5 million of 0.625 % Convertible Senior Notes which were due and paid in 2023 (see Note 17, Interest Expense ). The Company amortized deferred financing costs and debt discounts over the term of the debt, using the effective interest method. Interest expense also includes stated interest in connection with the Company's debt instruments. 123 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) Income Taxes The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and deferred tax liabilities are determined based on differences between their financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. When appropriate, valuation allowances are established to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for uncertain tax positions in its consolidated financial statements when it is more-likely-than-not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently estimated as the largest amount of the tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authorities, assuming full knowledge of the position and relevant facts. The Company's policy is to recognize any interest and penalties related to income taxes as I ncome tax expense in the relevant period. Recently Issued Accounting Pronouncements Accounting Pronouncements Adopted ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740) - On December 14, 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 amends ASC 740, Income Taxes, to expand income tax disclosures and requires that the Company disclose (i) the income tax rate reconciliation using both percentages and reporting currency amounts; (ii) specific categories within the income tax rate reconciliation; (iii) additional information for reconciling items that meet a quantitative threshold; (iv) the composition of state and local income taxes by jurisdiction; (v) pretax income (loss) from continuing operations disaggregated by jurisdiction and (vi) the amount of income taxes paid disaggregated by jurisdiction. The Company adopted ASU 2023-09 for the year ended December 31, 2025, on a prospective basis. See Note 12, Income Tax Expense (Benefit) . Accounting Pronouncements Not Yet Adopted ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220) - The new standard, issued in November 2024, requires additional disclosure in tabular format, about the nature of specific types of expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standard does not change the requirements for the presentation of expenses on the face of the income statement. The standard is effective with annual periods beginning after December 15, 2026. Early adoption and retrospective application are permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2027. We expect ASU 2024-03 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements. ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40) - Targeted Improvements to the Accounting for Internal-Use Software (Topic 350) - The new standard, issued in September 2025, modernizes the accounting for internal-use software. ASU 2025-06 removes all references to software development stages and requires capitalization of software costs when management has committed to the software project and it is probable the software will be completed and perform its intended use. The Company plans to adopt the guidance for the fiscal year ending December 31, 2028. The Company is currently evaluating the method of its adoption of ASU 2025-06, and the effects the adoption of this guidance will have on the consolidated financial statements. 124 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 2. Summary of Significant Accounting Policies (Continued) ASU 2025-11, Interim Reporting - Narrow-Scope Improvements (Topic 270) - The new standard, issued in December 2025, clarifies the interim reporting requirements by improving navigability of Topic 270 and more clearly specifies what disclosures are required in an interim reporting period. It is not intended to significantly change interim reporting or expand or reduce interim disclosure requirements. The standard is effective for interim reporting periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2028. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements. 3. Sage Acquisition On July 31, 2025 (the Sage Closing Date), the Company completed its acquisition of all the outstanding equity of Sage Therapeutics, Inc. pursuant to the Merger Agreement dated June 13, 2025 (the Sage Acquisition). Under the terms of the Merger Agreement, the Company commenced a tender offer to acquire all outstanding shares of Sage, par value $ 0.0001 per share (the Shares and each, a Share), at an offer price of (i) $ 8.50 per share in cash, less any applicable withholding taxes and without interest (the Cash Amount; an aggregate of approximately $ 561 million paid as of the acquisition date), plus (ii) one contingent value right per Share (the CVR; an aggregate of approximately $ 234 million, subject to the achievement of specific contingencies), which represents the right to receive up to $ 3.50 , which is governed by the terms of a contingent value rights agreement entered into between the Company and CVR agent (the Sage CVR Agreement), in cash, less any applicable withholding taxes and without interest. The transaction provides Supernus with the right to develop and market ZURZUVAE® (zuranolone) capsules, the first and only FDA approved oral medicine indicated for the treatment of adults with postpartum depression, and a late-stage product candidate. For the year ended December 31, 2025, the Company incurred transaction costs of approximately $ 10.0 million to complete the acquisition, which were included in Selling, general and administrative expense in the consolidated statements of earnings (loss). Contingent payments of up to $ 234 million are due to the sellers upon the achievement of certain milestones related to the development and commercial sale of ZURZUVAE. In connection therewith, the Company recorded a contingent consideration liability of $ 11.4 million as of the date of acquisition to reflect the estimated fair value of the contingent consideration. The estimated fair value of the contingent consideration was determined using a market participant approach with both implied fair value from the stock price combined with a Monte Carlo simulation for the sales-based milestones, and income approach for the other milestones. The key assumptions considered include the estimated amount and timing of projected revenues, probability of milestone achievement, volatility, implied market value at acquisition date, estimated discount rates, and risk-free interest rate. In each reporting period after the acquisition, the Company will revalue the contingent consideration liability and will record increases or decreases in the fair value of the liability in its consolidated statements of earnings (loss). Changes in fair value will result from changes in actual and projected milestone achievement, as well as changes to forecasts. The inputs and assumptions may not be observable in the market, but reflect the assumptions the Company believes would be made by a market participant. The possible outcomes for the contingent consideration range from $ 0 to $ 234 million on an undiscounted basis. See Note 7, Contingent Consideration, for further discussion. In connection with the acquisition, the vesting of certain outstanding Sage stock options, restricted stock units, and performance stock units were accelerated upon closing of the acquisition and replaced with the right to receive one CVR per share. The purchase price for Sage includes $ 4.1 million related to Sage awards where vesting was accelerated in connection with the acquisition. The Company recognized compensation expense of $ 25.0 million in the post-combination period for the year ended December 31, 2025 related to awards that were accelerated to vest upon closing of the acquisition and for the portion of potential CVR payments to former Sage employees which are considered probable under the employee compensation accounting model. The Company will continue to evaluate whether the remaining portion of potential CVR payments to former Sage employees are considered probable under the employee compensation accounting model, and will recognize compensation expense if and when they become probable. See Note 10, Share-based Payments , for further discussion. 125 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 3. Sage Acquisition (Continued) The acquisition is being accounted for as a business combination under the acquisition method of accounting, in accordance with ASC 805, Business Combinations . The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The estimated fair values of the assets acquired and liabilities assumed, including goodwill , have been included in the Company's consolidated financial statements since the Sage Closing Date. The Company's accounting for this acquisition is preliminary, and fair value estimates for the assets acquired and liabilities assumed and the Company's estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period. During the measurement period, if the Company obtains new information regarding facts and circumstances that existed as of the Sage Closing Date that, if known, would have resulted in revised estimated values of those assets or liabilities, the Company will accordingly revise its estimates of fair values and purchase price allocation. The effect of measurement period adjustments on the estimated fair value elements will be reflected as if the adjustments had been made as of the Sage Closing Date. The impact of all changes that do not qualify as measurement period adjustments will be included in current period earnings. The Company expects to finalize its purchase price allocation within one year of the Sage Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record at fair value the assets acquired and liabilities assumed in the following areas: inventory, prepaid and other assets, intangible assets, tax assets and liabilities, and certain existing or potential reserves, including those for legal or contract-related matters. The activities the Company is currently undertaking, include but are not limited to the following: review of acquired contracts and other contract-related and legal matters; review and evaluation of the accounting policies, tax positions, and other tax-related matters. Further, the Company is in the process of obtaining input from third party valuation firms with respect to the fair value of the acquired intangible assets and inventory, and other information necessary to record and measure the assets acquired and liabilities assumed. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Sage Closing Date are subject to change. 126 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 3. Sage Acquisition (Continued) The following preliminary purchase price allocation table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Sage Closing Date and subsequent measurement period adjustments recorded (unaudited, dollars in thousands): As Initially Reported Measurement Period Adjustments (1) As Adjusted Cash and cash equivalents $ 243,197 $ — $ 243,197 Marketable securities 93,181 — 93,181 Accounts receivable, net 23,291 — 23,291 Inventories, net (2) 50,714 1,897 52,611 Prepaid expenses and other current assets (2) 18,674 ( 2,094 ) 16,580 Restricted cash 1,450 — 1,450 Operating lease asset (3) 5,630 ( 520 ) 5,110 Intangible assets (4) 166,500 ( 29,500 ) 137,000 Deferred income tax assets, net (5) — 48,384 48,384 Other assets 1,102 — 1,102 Total fair value of assets acquired 603,739 18,167 621,906 Accounts payable and accrued liabilities 44,232 — 44,232 Other liabilities (6) — 23,969 23,969 Operating lease liability 12,380 — 12,380 Total fair value of liabilities assumed 56,612 23,969 80,581 Total identifiable net assets 547,127 ( 5,802 ) 541,325 Goodwill 2,061 5,802 7,863 Total purchase price $ 549,188 $ — $ 549,188 Cash consideration paid for Sage's common stock $ 533,667 — $ 533,667 Cash consideration paid for cash settlement of Sage's equity awards 4,073 — 4,073 Fair value of contingent consideration 11,448 — 11,448 Total purchase price $ 549,188 $ — $ 549,188 (1) Measurement period adjustments reflect changes based on information related to the facts and circumstances that existed as of the acquisition date. (2) Measurement period adjustment related to the refinement of the acquired inventory population. (3) Refinement of the estimate of fair value of the right of use asset associated with the acquired Sage headquarters lease. Refer to Note 13, Leases. (4) Measurement period adjustments to intangible assets are primarily due to update in inputs and assumptions based on information related to the facts and circumstances that existed as of the acquisition date. (5) Represents the preliminary income tax impact of the transaction. (6) Measurement period adjustment related to the Company's accounting policy related to the collaboration arrangement with Biogen. 127 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 3. Sage Acquisition (Continued) Acquired Inventory The fair value of the inventory was estimated using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or to dispose of the inventory, as well as a profit on the sale. Acquired Lease As part of the Sage Acquisition, the Company acquired a lease for commercial real estate. The Company recognized a right-of-use asset and operating lease liability at the acquisition date. The amounts recognized reflect the present value of remaining lease payments, discounted at the Company's incremental borrowing rate. The fair value of the lease ROU asset was measured at an amount equal to the lease liability and evaluated for favorable or unfavorable lease terms when compared with market terms. Refer to Note 13, Leases, for further discussion of the acquired lease asset and assumed lease liability. Acquired Intangible Assets The acquired intangible asset includes the acquired developed technology and product rights. The Company estimated the fair value of the acquired intangible asset as of the Sage Closing Date using the income approach. The fair value measurements of the acquired intangible asset was estimated based on significant unobservable inputs and therefore, represent a Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the intangible assets valuation include: the estimated future cash flows from product sales, probability of achieving regulatory approval in certain territories, the timing and projection of costs and expenses, and discount rates. The following table summarizes the purchase price allocation, and the average remaining useful lives for identifiable intangible assets (dollars in thousands): Fair Value Estimated Useful Lives (in years) Acquired developed technology and product rights $ 137,000 8 Total intangible assets $ 137,000 Acquired intangible assets are amortized over their estimated useful lives on a straight-line basis. Acquired Deferred Income Tax Assets, net The deferred income tax assets, net relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets, inventory, and net operating loss carryforwards, partially offset by other temporary differences. The acquired federal and state net operating loss carryforwards is reduced by a valuation allowance for amounts that are not expected to be realizable in the future. Refer to Note 12, Income Tax Expense (Benefit) . Goodwill Goodwill was calculated as the excess of the consideration paid consequent to completing the acquisition, compared to the net assets recognized. Goodwill represents the future economic benefits from the other acquired assets, and which could not be individually identified and separately valued. Goodwill is primarily attributable to the additional acquired growth platforms, tax attributes, and an expanded revenue base. Goodwill is not deductible for tax purposes . Revenues and Net Earnings (Loss) of Sage The operations of Sage and its subsidiaries have been included in the Company's consolidated statements of earnings (loss) for the period subsequent to the Sage Closing Date, and through December 31, 2025. Total revenues of $ 68.1 million and net loss of $ 63.3 million were recorded from the Sage Closing Date through the period ended December 31, 2025. 128 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 3. Sage Acquisition (Continued) Pro forma Information The following table presents the unaudited pro forma combined financial information for each of the periods presented as if the Sage Acquisition had occurred on January 1, 2024 (dollars in thousands): Year Ended December 31, 2025 2024 (unaudited) Pro forma total revenues $ 772,211 $ 703,060 Pro forma net loss $ ( 142,793 ) $ ( 406,677 ) The unaudited pro forma combined financial information is based on historical financial information and the Company's preliminary allocation of purchase price; therefore, it is subject to subsequent adjustment upon finalization of the purchase price allocation. In order to reflect the occurrence of the acquisition as if it had occurred on January 1, 2024, the unaudited pro forma combined financial information reflects the recognition of amortization expense on the acquired intangible asset; the estimated reduction in the Company's interest income generated from marketable securities that were liquidated to fund the purchase price of the Sage Acquisition, and the estimated tax impact of the pro forma adjustments. The unaudited pro forma combined financial information also reflects the recognition of material non-recurring costs incurred directly as a result of the Sage Acquisition primarily pertaining to the following: • Transaction-related expenses incurred by the Company of $ 10.0 million during the year ended December 31, 2025, are assumed to have occurred on the pro forma close date of January 1, 2024, and recognized as if incurred in the first quarter of 2024; • Post-combination employee-related expenses incurred by the Company of $ 38.3 million that were incurred during the year ended December 31, 2025, are assumed to have occurred on the pro forma close date of January 1, 2024, and recognized as if incurred in the first quarter of 2024; • Post-combination share-based compensation expense of $ 22.9 million related to awards that were accelerated and settled by Supernus on the closing date are assumed to have occurred on the pro forma close date of January 1, 2024, and recognized as if incurred in the first quarter of 2024. This amount does not reflect any post-combination expense related to potential CVR payments to former Sage employees because the payment was not considered probable under the employee compensation accounting model as of the acquisition date. In the fourth quarter of 2025, the Company determined a CVR milestone is probable of achievement. As such, the Company recognized an additional $ 2.1 of stock-based compensation for Sage equity awards that also had a CVR right (accounted for under the employee compensation accounting model). The Company did not make a pro forma adjustment, as the post-combination expense is reflected in the 2025 annual financial statements. The unaudited pro forma combined financial information should not necessarily be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results . 129 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 4. Disaggregated Revenues The following table provides information regarding total revenues (dollars in thousands): Year Ended December 31, 2025 2024 2023 Net product sales Qelbree $ 304,654 $ 241,273 $ 140,192 GOCOVRI 146,824 130,824 119,637 Oxtellar XR 40,700 99,464 113,404 APOKYN 47,771 73,926 75,083 Trokendi XR 42,421 63,201 94,336 ONAPGO 17,254 — — Other (1) 26,912 29,008 31,281 Total net product sales 626,536 637,696 573,933 Collaboration revenue (ZURZUVAE) 52,996 — — Royalty, licensing, and other revenues 39,420 24,121 33,588 Total revenues $ 718,952 $ 661,817 $ 607,521 ______________________________ (1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER. We recognized $ 15.0 million of licensing revenue for the year ended December 2025 related to the achievement of a regulatory milestone under our collaboration agreement with Shionogi. In December 2023, the Company submitted to the FDA a notification of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024. The Company recognized noncash royalty revenues of $ 4.0 million for the year ended December 31, 2023. The Company no longer recognizes noncash royalty revenue as ownership of the royalty rights reverted back to the Company during the second quarter of 2023 (see Note 2, Summary of Significant Accounting Policies). Adjustments related to prior year sales in 2025 and 2024 was less than 4 % of net product sales for each respective period. The majority of the adjustment is attributable to Qelbree, reflecting favorable actual returns experienced in 2025 and 2024. As a result, the Company changed its estimated provision for product returns based on the most recent experience. In 2023, adjustments related to prior year sales amounted to less than 1 % of net product sales. 130 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 4. Disaggregated Revenues (Continued) The following table shows the percentage of net product sales to total net product sales: Percentage of Net Product Sales Year Ended December 31, 2025 2024 2023 Qelbree 49 % 38 % 24 % GOCOVRI 23 % 20 % 21 % Oxtellar XR 6 % 16 % 20 % APOKYN 8 % 12 % 13 % Trokendi XR 7 % 10 % 16 % ONAPGO 3 % — % — % Other (1) 4 % 4 % 6 % Total 100 % 100 % 100 % ______________________________ (1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER. The Company does not currently own or operate manufacturing facilities for the commercial production of any of our commercial products. The Company currently depends on third-party contract manufacturing organizations (CMOs), who offer a comprehensive range of contract manufacturing and packaging services, in various countries for the supply of API, finished goods for our commercial products. For most of our commercial products, we rely on single source suppliers to produce and package final dosage forms for our products and raw materials, including API. On November 4, 2025, the Company announced that due to stronger than expected demand for ONAPGO, supplier constraints are impacting the Company's ability to fully meet this demand. ONAPGO is manufactured in Europe, supplied to us by our ONAPGO licensing partner, and packaged in the U.S. by a third-party CMO. The Company relies on single source suppliers to produce and package final dosage forms for ONAPGO. On February 24, 2026, the Company announced that it has made progress in securing additional product supply of ONAPGO from the current supplier and as a result, has resumed new patient initiation. In addition, the Company is working with a second supplier that is expected to begin supplying ONAPGO in 2027. A change in any of the suppliers would require regulatory approval which could cause a further delay in manufacturing and a possible loss of sales, which could affect future operating results adversely. 5. Investments Marketable Securities Unrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands): December 31, 2025 December 31, 2024 Corporate, U.S. government agency and municipal debt securities Amortized cost $ 180,215 $ 384,481 Gross unrealized gains 34 89 Gross unrealized losses ( 27 ) ( 289 ) Total fair value $ 180,222 $ 384,281 As of December 31, 2025, all of the Company's unrestricted available-for-sale marketable securities have contractual maturities of one year or less. There was no impairment on any available-for-sale marketable securities as of December 31, 2025 and December 31, 2024. 131 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Financial Statements (Continued) 5. Investments (Continued) Investment in Navitor In April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase 2 clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase 1 and Phase 2 development costs incurred by either party, up to a maximum of $ 50 million, which amount could be increased under the terms of the Development Agreement upon Navitor Inc.’s request and the Company’s consent. In 2020, the Company paid a one-time, nonrefundable, and non-creditable fee of $ 10 million for the option to acquire or license NV-5138 (SPN-820) and made a $ 15 million equity investment representing approximately 13 % ownership in Navitor Inc. There are also certain additional payments which could be incurred by the Company that are contingent upon Navitor Inc. achieving defined milestones. These payments include an additional license or acquisition fee depending on whether the Company ultimately licenses or acquires NV-5138 (SPN-820), and subsequent clinical, regulatory and sales milestone payments. The total payments, exclusive of the royalty payments on net sales of NV-5138 (SPN-820) and development costs paid by the Company under the agreement, have the potential to reach $ 410 million to $ 475 million, which includes an aggregate upfront payment of $ 25 million paid in 2020 for the option to acquire or license NV-5138 (SPN-820) and the equity investment, an additional license or acquisition fee depending on whether the Company ultimately licenses or acquires NV-5138 (SPN-820), and subsequent clinical, regulatory and sales based milestone payments. The Company also will have the first right of refusal for any compound with a similar mechanism of action to NV-5138 (SPN-820) on mTORC1 in the central nervous system. In addition to entering into the Development Agreement in April 2020, as mentioned above, the Company acquired Series D Preferred Shares of Navitor Inc. (the Navitor Shares), an equity investment representing an approximately 13 % ownership position in Navitor Inc. As part of a legal restructuring in March 2021, the Company's Navitor Inc. Shares were exchanged for membership interests in Navitor Pharmaceutics LLC (Navitor LLC), which became the sole shareholder of Navitor Inc. The Company has determined that although Navitor LLC is a VIE, the Company does not consolidate the results of this VIE into its financial results because the Company lacks the power to direct the activities that most significantly impact Navitor LLC’s economic performance. In the second quarter of 2024, the Company consented to payment of additional Phase 2 development costs for NV-5138 (SPN-820) as they are incurred, but reserves the right to terminate payment of future development costs at its discretion. On May 5, 2025, the Company entered into a binding memorandum of understanding (MOU) with Navitor Inc. Under the MOU, the Company agreed to conduct further development activities at its own cost and Navitor Inc. agreed to waive its right to receive the $ 100 million Initial Acquisition Fee under the Development Agreement. In addition, pursuant to the MOU the Company exercised the Purchase Option to purchase all assets of Navitor and its affiliates pursuant to the Development Agreement, subject to, among other things, completion of satisfactory due diligence by the Company, and negotiation and execution of a definitive Purchase Agreement. On June 24, 2025, October 31, 2025 and December 22, 2025, the Company amended the MOU with Navitor to extend the negotiation period. The maximum exposure to losses related to Navitor LLC includes the approximately $ 50.0 million for Phase 1 and Phase 2 development of NV-5138 (SPN-820) already paid by the Company, plus the cost of other development and formulation activities provided by the Company and additional Phase 2 development costs the Company agreed to pay pursuant to the Development Agreement. Subsequent to the Development Agreement entered into in 2020, no additional equity investment has been made or financing has been provided to Navitor Inc. or Navitor LLC. The Company records its share of the results of Navitor LLC, a private company, on a quarter lag as the financial information of Navitor LLC is not available on a sufficiently timely basis for the Company to apply the equity method of accounting. 132 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 6. Fair Value of Financial Instruments The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants. The Company reports the fair value of assets and liabilities using a three-level measurement hierarchy that prioritizes the inputs used to measure fair value. The fair value hierarchy consists of the following three levels: • Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets. • Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves). • Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data. The fair value of the restricted marketable securities which are classified as Level 2 financial assets are recorded in Other assets on the consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. Financial Assets and Liabilities Recorded at Fair Value on a Recurring Basis The Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands): Fair Value Measurements Total Fair Value at December 31, 2025 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents Cash $ 56,371 $ 56,371 $ — $ — Money market funds 72,077 72,077 — — Marketable securities Corporate debt securities 164,519 — 164,519 — Municipal debt securities 14,716 — 14,716 — U.S government agency securities 987 — 987 — Other noncurrent assets Marketable securities - restricted (SERP) 705 27 678 — Restricted cash 1,450 1,450 — — Total assets at fair value $ 310,825 $ 129,925 $ 180,900 $ — Liabilities: Contingent consideration $ 31,258 $ — $ — $ 31,258 Total liabilities at fair value $ 31,258 $ — $ — $ 31,258 133 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 6. Fair Value of Financial Instruments (Continued) Fair Value Measurements Total Fair Value at December 31, 2024 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents Cash $ 37,830 $ 37,830 $ — $ — Money market funds 31,501 31,501 — — Marketable securities Corporate debt securities 355,201 — 355,201 — U.S. government agency debt securities 29,080 — 29,080 — Other noncurrent assets Marketable securities - restricted (SERP) 635 21 614 — Total assets at fair value $ 454,247 $ 69,352 $ 384,895 $ — Liabilities: Contingent consideration $ 47,340 $ — $ — $ 47,340 Total liabilities at fair value $ 47,340 $ — $ — $ 47,340 Other Financial Instruments The carrying amounts of other financial instruments, including accounts receivable, accounts payable, accrued expenses, and other current liabilities approximate fair value due to their short-term maturities. 7. Contingent Consideration The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition, Adamas Acquisition, and Sage Acquisition (as defined below) (dollars in thousands): December 31, 2025 December 31, 2024 Reported under the following captions in the consolidated balance sheets: Contingent consideration, current portion $ 31,052 $ 47,340 Contingent consideration, long-term 206 — Total $ 31,258 $ 47,340 The Company's contingent consideration liabilities are related to the USWM Acquisition in 2020, the Adamas Acquisition in 2021, and the Sage Acquisition in 2025. The contingent consideration liabilities are measured at fair value on a recurring basis using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement. The change in fair value is reported on the consolidated statement of earnings (loss) in Contingent consideration loss (gain) . USWM Contingent Consideration On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments for regulatory and development milestones and sales-based milestones. At December 31, 2024, there were two remaining outstanding milestones, one related to the approval of ONAPGO and the other related to the commercial launch of ONAPGO. Both milestones were met in 2025 and the liability was accreted to the milestone amounts due, 134 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 7. Contingent Consideration (Continued) resulting in the recognition of $ 7.7 million change in fair value of contingent consideration during 2025. In February 2025, the Company paid the $ 25 million milestone related to the FDA's approval of ONAPGO. ONAPGO was launched in April 2025, and the $ 30 million milestone payment related to the commercial launch of ONAPGO, subject to certain holdbacks as permitted under the Sale and Purchase Agreement Relating to USWM Enterprises, LLC, dated April 28, 2020, by and between US WorldMeds Partners, LLC and Supernus Pharmaceuticals, Inc., (USWM Sale and Purchase Agreement), became due and payable. Of the $ 30 million, the Company paid $ 2.3 million in the second quarter, and the remaining amount held was reclassified to Other current liabilities in the consolidated balance sheet in the second quarter of 2025 as the milestone had been met but payment remains subject to certain holdbacks permitted under the USWM Sale and Purchase Agreement. The Company paid $ 1.9 million in principal amount held back in the third quarter of 2025. The outstanding liability as of December 31, 2025 was $ 26.6 million, which included the principal amount held back and interest. During the third quarter of 2025, USWorldsMeds Partners, LLC filed a complaint in the Superior Court of the State of Delaware seeking payment for the withheld amount, plus interest, attorney's fees and costs. The key assumptions considered in estimating the fair value included the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, and the discount rate. Adamas Contingent Consideration On November 24, 2021 (the Adamas Closing Date), the Company completed its acquisition of all the outstanding equity of Adamas (Adamas Acquisition). The Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI. Each CVR represents the contractual right to receive a contingent payment of $ 0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer & Trust Company, LLC, as rights agent, as further defined in the CVR agreement. One Milestone Payment was payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $ 150 million during any consecutive twelve-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment was payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $ 225 million during any consecutive twelve-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once. As of December 31, 2024, the Milestone 2024 was not met. As of December 31, 2025, the 2025 Milestone was also not met. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones included the estimated revenue projections and the probability of achievement of the milestone. Sage Contingent Consideration On July 31, 2025, the Company completed the Sage Acquisition. The Sage Acquisition included payment of one contingent value right (Sage CVR) which represents the right to receive up to $ 3.50 , which is governed by the terms of a contingent value rights agreement entered into between the Company and CVR agent (Sage CVR Agreement), in cash, less any applicable withholding taxes and without interest. Subject to the terms of the Sage CVR Agreement, (1) $ 1.00 per share would be payable if in any calendar year between closing and end of 2027, annual net sales (as defined in the Sage CVR Agreement) of ZURZUVAE allocable to Supernus or any of its affiliates reach $ 250 million or more in the U.S., (2) $ 1.00 per share would be payable if in any calendar year between closing and end of 2028, annual net sales (as defined in the Sage CVR Agreement) of ZURZUVAE allocable to Supernus or any of its affiliates reach $ 300 million or more in the U.S., (3) $ 1.00 per share would be payable if in any calendar year between closing and end of 2030, annual net sales (as defined in the Sage CVR Agreement) of ZURZUVAE allocable to Supernus or any of its affiliates reach $ 375 million or more in the U.S., and (4) $ 0.50 per share would be payable upon the first commercial sale in 135 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 7. Contingent Consideration (Continued) Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder (MDD) in Japan by June 30, 2026. The maximum amount payable with respect to a CVR issued in respect to each Share is $ 3.50 , an aggregate of approximately $ 234 million. See Note 3, Sage Acquisition, for the key assumptions used in the valuation of the contingent consideration liability related to the Sage Acquisition. Change in the Fair Value of Contingent Consideration The following table provides a reconciliation of the beginning and ending balances related to the C ontingent consideration liabilities for the USWM Acquisition, Adamas Acquisition, and Sage Acquisition (dollars in thousands): USWM Acquisition Adamas Acquisition Sage Acquisition Total Balance, December 31, 2022 $ 46,270 $ 8,697 $ — $ 54,967 Change in fair value recognized in earnings 130 ( 1,647 ) — ( 1,517 ) Balance, December 31, 2023 46,400 7,050 — 53,450 Change in fair value recognized in earnings 940 ( 7,050 ) — ( 6,110 ) Balance, December 31, 2024 47,340 — — 47,340 Contingent consideration from Sage Acquisition recognized at Sage Closing Date — — 11,448 11,448 Change in fair value recognized in earnings - share-based compensation — — 2,051 2,051 Change in fair value recognized in earnings 7,660 — 17,759 25,419 Milestone payments ( 27,295 ) — — ( 27,295 ) Reclassification to Other Current Liabilities ( 27,705 ) — — ( 27,705 ) Balance, December 31, 2025 $ — $ — $ 31,258 $ 31,258 The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones: • For the year ended December 31, 2025, the Company recorded a $ 7.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones. The change in fair value of contingent consideration was primarily due to accretion to the full milestone payment amount with the achievement of the milestones. ONAPGO was approved by the FDA in February 2025 and was launched in April 2025. • For the year ended December 31, 2024, the Company recorded a $ 0.9 million expense which was primarily driven by the passage of time as well as the change in timing of milestone achievement and estimated discount rate. • For the year ended December 31, 2023, the Company recorded a $ 0.1 million expense which was primarily driven by the passage of time and the accretion to the payout amount related to the milestone achieved in the first quarter of 2022. The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs: • For the year ended December 31, 2025, there was no outstanding contingent consideration liability related to the Adamas CVR. • For the year ended December 31, 2024, the Company recorded a $ 7.1 million gain primarily driven by the non achievement of Milestone 2024. • For the year ended December 31, 2023, the Company recorded a $ 1.6 million gain which was primarily due to changes in market data and revenue projections. 136 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 7. Contingent Consideration (Continued) The Company recorded the following changes in the fair value of the contingent consideration liability for the Sage CVRs: • The Company recorded a contingent consideration liability of $ 11.4 million at the Sage Closing Date. The Company recorded $ 19.8 million expense due to the change in fair value during the year ended December 31, 2025. The $ 19.8 million change in fair value consisted of : (i) $ 2.1 million change in fair value for the Sage CVRs associated with the Sage equity awards which were accelerated vested at the Sage Closing Date. These were accounted for under the employee compensation accounting model and the change in fair value was recorded as share-based compensation expense in S elling, general and administrative expense line in the statement of earnings (loss); (ii) $ 17.8 million change in fair value which was recorded under C ontingent consideration gain (loss) line in the statement of earnings (loss). The change was primarily driven by an increase in the probability of achievement for the milestone related to the first commercial sale in Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder (MDD) in Japan by June 30, 2026. ZURZUVAE received regulatory approval for the treatment of MDD in Japan in December 2025. 8. Goodwill and Intangible Assets, Net Goodwill The following table sets forth the gross carrying amounts of goodwill (dollars in thousands): December 31, 2025 December 31, 2024 Beginning balance $ 117,019 $ 117,019 Goodwill from Sage Acquisition (1) 7,863 — Ending balance $ 124,882 $ 117,019 (1) Refer to Note 3, Sage Acquisition for further detail. There were no goodwill impairment charges recognized in 2025 or 2024. Intangible Assets, Net The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets (dollars in thousands): December 31, 2025 December 31, 2024 Remaining Weighted Average Life (Years) Carrying Amount, Gross Accumulated Amortization Carrying Amount, Net Carrying Amount, Gross Accumulated Amortization Carrying Amount, Net Acquired in-process research and development $ — $ — $ — $ 124,000 $ — $ 124,000 Intangible assets subject to amortization: Acquired developed technology and product rights 6.37 922,311 ( 352,855 ) 569,456 661,311 ( 263,399 ) 397,912 Capitalized patent defense costs — 43,820 ( 43,820 ) — 43,820 ( 43,820 ) — Total intangible assets 6.37 $ 966,131 $ ( 396,675 ) $ 569,456 $ 829,131 $ ( 307,219 ) $ 521,912 Amortization expense for intangible assets was $ 89.5 million, $ 78.0 million, and $ 82.4 million for the years ended December 31, 2025, 2024, and 2023, respectively. 137 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 8. Goodwill and Intangible Assets, Net (Continued) In February 2025, the FDA approved ONAPGO and as such, the research and development efforts for the Company's acquired in-process research and development asset is considered complete. As of the FDA approval date, the ONAPGO intangible asset is a definite-life intangible asset subject to amortization and has a useful life of 10 years. In July 2025, the Company acquired ZURZUVAE (zuranolone), the first and only FDA-approved oral medicine indicated for the treatment of PPD in adults. The ZURZUVAE intangible asset is a definite-lived intangible asset subject to amortization and has a useful life of 8 years. Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Trokendi XR and Oxtellar XR will expire no earlier than 2027. The Company entered into settlement agreements that allowed third parties to enter the Trokendi XR market on January 1, 2023. The Company entered into settlement and license agreements that allowed a third party to enter the Oxtellar XR market in September 2024. The Company has entered into settlement agreements with third parties permitting the sale of a generic version of GOCOVRI beginning in June 2029, or sooner under certain conditions. The Company entered into settlement and license agreements that allows third parties to enter the XADAGO market in December 2027, or sooner under certain conditions. In the fourth quarter of 2023, the Company recognized impairment charges of $ 20.2 million related to some of its acquired intangible assets, primarily XADAGO. The primary factors that led to the impairment determinations were the following: (1) the performance of the commercial products; (2) forthcoming loss of exclusivity of XADAGO; and (3) the change in the Company's future outlook of the brands. The Company recognized as impairment loss the difference between the estimated fair values and carrying values of these intangible assets. The Company used the discounted cash flow income approach to estimate the fair values of each of these intangible assets. The primary inputs and assumptions used in the model included timing and projections of estimated future revenues and cash flows, loss of exclusivity, and discount rate. The fair value measurement is classified as Level 3 within the fair value hierarchy as defined in ASC 820, Fair Value Measurement , due to the unobservable inputs used. The impairment loss is reported as Intangible asset impairment charges in the consolidated statements of earnings (loss). The following table sets forth the anticipated annual amortization expense for definite-lived intangible assets. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors (dollars in thousands): Year: Estimated Amortization Expense 2026 $ 100,588 2027 100,456 2028 99,013 2029 99,013 2030 45,315 Thereafter 125,071 9 . Debt Uncommitted Demand Secured Line of Credit On February 8, 2023, the Company entered into a credit line agreement with UBS (Credit Line). The Credit Line provides for a revolving line of credit of up to $ 150 million, which can be drawn at any time. Any fixed rate borrowing will bear interest at a fixed interest rate, equal to the sum of (i) the UBS Fixed Funding Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line. Any variable rate borrowing will bear interest at a variable interest rate, equal to the sum of (i) the UBS Variable Rate (as defined in the Credit Line) plus (ii) the applicable Percentage Spread established in the Credit Line. 138 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 9. Debt (Continued) The Credit Line is secured by a first priority lien and security interest in certain of the Company’s assets, including each account of the Company at UBS Financial Services Inc. (the Collateral Account), and other such collateral (collectively, the Collateral), as further defined in the Credit Line. The Company may be required to post additional collateral if the value of the Collateral declines below the required collateral maintenance requirements. Upon certain customary events of default, all amounts due under the Credit Line will become immediately due and payable without demand, and UBS has the right, in its discretion, to liquidate, transfer, withdraw or sell all or any part of the Collateral and apply the proceeds to repay any borrowings pursuant to the Credit Line. The Company has the right to repay any variable rate advance under the Credit Line at any time, in whole or in part, without penalty. The Company may repay any fixed rate advance in whole, but may not repay any fixed rate advance in part. In its discretion and without cause, UBS has the right at any time to demand full or partial payment of amounts borrowed pursuant to the Credit Line and terminate the Credit Line. As of December 31, 2025 and December 31, 2024, there was no outstanding debt under the Credit Line. 10. Share-Based Payments Common Stock The holders of the Company's common stock are entitled to one vote for each share of common stock held. Equity Incentive Plan The Company has adopted the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (2021 Plan) which was approved by the stockholders in June 2021. The 2021 Plan is the successor to, and replaced the 2012 Equity Incentive Plan, as amended (the 2012 Plan). The 2021 Plan is administered by the Company's Board of Directors and the Company's Compensation Committee of the Board. The 2021 Plan provides for the grant of stock options and certain other equity awards, including: stock appreciation rights (SARs); restricted and unrestricted stock; stock units; performance awards; cash awards; and other awards that are convertible into or otherwise based on the Company's common stock, to the Company's key employees, directors, consultants, and advisors. On June 14, 2024, the Company's shareholders approved, and the Company has adopted, the Amended and Restated 2021 Equity Incentive Plan (the Amended 2021 Plan) to increase the number of shares of the Company's common stock available for issuance under the 2021 Plan by 4,000,000 shares. The maximum number of shares that can be issued under the Amended 2021 Plan is 15,012,893 shares of the Company's common stock which includes the (i) 4,000,000 shares added pursuant to the adoption of the Amended 2021 Plan, (ii) the number of shares that remain available to be issued or transferred pursuant to awards under the 2021 Equity Incentive Plan as of the adoption date of the Amended 2021 Plan, and (iii) the number of shares that have already been issued or transferred pursuant to awards under the 2021 Plan prior to the approval by the Company’s stockholders of the Amended 2021 Plan. Option awards are granted with an exercise price equal to the closing price of the Company's common stock as of the grant date. Options and awards granted have a ten-year contractual term. Options and awards granted to employees, consultants and advisors generally vest in four equivalent annual installments, starting on the first anniversary of the grant's date. Options and awards granted to the directors generally vest over a one-year term. Employee Stock Purchase Plan The Company has adopted the Supernus Pharmaceuticals, Inc. 2012 Employee Stock Purchase Plan (as amended to date, the ESPP). The ESPP allows eligible employees the opportunity to acquire shares of the Company's common stock at periodic intervals through accumulated payroll deductions. These deductions are applied at the semi-annual purchase dates of June 30 and December 31 to purchase shares of common stock from the Company at a discount. Eligible employees may purchase shares at the lower of 85 % of the fair market value at either the first day of the purchase period or the fair market value at the end of the purchase period. The ESPP provides for the issuance of up to 1,700,000 shares of the Company's common stock. The Company records compensation expense related to its ESPP. 139 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 10. Share-Based Payments (Continued) Share-based compensation expense Share-based compensation expense is as follows (dollars in thousands): Year Ended December 31, 2025 2024 2023 Research and development $ 5,729 $ 5,148 $ 4,743 Selling, general and administrative (1) 50,243 22,607 22,016 Total $ 55,972 $ 27,755 $ 26,759 (1) Includes $ 25.0 million of compensation expense related to the acceleration of certain Sage equity awards in connection with the Sage Acquisition in July 2025 and certain CVRs granted to holders of the accelerated Sage equity awards which became probable of achievement in the fourth quarter of 2025. The Company has $ 12.3 million of unrecognized compensation expense related to CVRs granted to holders of the accelerated Sage equity awards. This unrecognized compensation expense will be recognized if and when the milestones associated with the CVRs become probable of achievement. Stock Option The following table summarizes stock option activities: Number of Options Weighted Average Exercise Price (per share) Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding, December 31, 2023 6,583,822 $ 29.20 5.9 $ 23,668 Granted 1,206,812 $ 28.29 Exercised ( 781,441 ) $ 16.12 Forfeited ( 290,120 ) $ 31.96 Outstanding, December 31, 2024 6,719,073 $ 30.44 5.9 $ 43,198 Granted 1,211,945 $ 35.14 Exercised ( 1,433,482 ) $ 24.37 Forfeited ( 154,527 ) $ 33.70 Outstanding, December 31, 2025 6,343,009 $ 32.63 6.3 $ 108,396 As of December 31, 2025 Vested and expected to vest 6,343,009 $ 32.63 6.3 $ 108,396 Exercisable 3,636,073 $ 32.08 4.8 $ 64,175 The weighted average grant date fair value of options granted for the years ended December 31, 2025, 2024, and 2023 were $ 20.16 , $ 16.57 , and $ 21.30 per share, respectively. The aggregate intrinsic value of options exercised for the years ended December 31, 2025, 2024, and 2023 were $ 27.6 million, $ 14.4 million, and $ 5.1 million, respectively. Proceeds from the options exercised for the years ended December 31, 2025, 2024, and 2023 were $ 34.9 million, $ 6.8 million, and $ 4.3 million, respectively. The total fair value of the underlying common stock related to options that vested during the years ended December 31, 2025, 2024, and 2023 were approximately $ 18.1 million, $ 16.7 million, and $ 14.8 million, respectively. 140 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 10. Share-Based Payments (Continued) The fair value of each option award is estimated on the date of the grant, using the Black-Scholes option-pricing model and the assumptions in the following table: Year Ended December 31, 2025 2024 2023 Fair value of common stock $ 32.48 - $ 48.32 $ 27.94 - $ 36.16 $ 27.66 - $ 38.60 Expected volatility 54.30 % - 55.15 % 55.56 % - 56.55 % 56.87 % - 58.22 % Expected dividend yield 0 % 0 % 0 % Expected term 5.87 years - 7.24 years 5.77 years - 7.91 years 5.60 years - 7.03 years Risk-free interest rate 3.75 % - 4.42 % 3.82 % - 4.57 % 3.27 % - 4.33 % As of December 31, 2025, the total unrecognized compensation expense was approximately $ 36.3 million. The Company expects to prospectively recognize these expenses over a weighted-average period of 2.5 years. Restricted Stock Units The following table summarizes restricted stock unit (RSU) activities: Number of RSUs Weighted- Average Grant Date Fair Value per Share Nonvested, December 31, 2023 300,141 $ 36.90 Granted 198,414 $ 28.06 Vested ( 100,891 ) $ 36.51 Forfeited ( 19,499 ) $ 34.71 Nonvested, December 31, 2024 378,165 $ 32.48 Granted 172,725 $ 33.50 Vested ( 137,923 ) $ 32.31 Forfeited ( 16,274 ) $ 32.52 Nonvested, December 31, 2025 396,693 $ 32.98 The total aggregate grant date fair value of RSUs that vested during the years ended December 31, 2025, 2024, and 2023 were $ 4.5 million, $ 3.7 million, and $ 1.5 million, respectively. Total aggregate vest date fair value of RSUs that vested during the years ended December 31, 2025, 2024, and 2023 were $ 4.6 million, $ 2.8 million and $ 1.8 million, respectively. As of December 31, 2025, the total unrecognized compensation expense was $ 8.3 million. The Company expects to prospectively recognize these expenses over a weighted-average period of 2.3 years. 141 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 10. Share-Based Payments (Continued) Performance Stock Units The following table summarizes performance share unit (PSU) activities: Performance-Based PSUs Market-Based Units Total PSUs Number of PSUs Weighted- Average Grant Date Fair Value per Share Number of PSUs Weighted- Average Grant Date Fair Value per Share Number of PSUs Weighted- Average Grant Date Fair Value per Share Nonvested, December 31, 2023 251,630 $ 32.22 20,000 $ 28.63 271,630 $ 31.96 Granted 252,700 $ 26.91 — $ — 252,700 $ 26.91 Vested ( 121,595 ) $ 31.68 — $ — ( 121,595 ) $ 31.68 Forfeited ( 58,050 ) $ 29.37 — $ — ( 58,050 ) $ 29.37 Nonvested, December 31, 2024 324,685 $ 28.80 20,000 $ 28.63 344,685 $ 28.79 Granted 246,496 $ 32.84 — $ — 246,496 $ 32.84 Vested ( 140,010 ) $ 29.95 ( 20,000 ) $ 28.63 ( 160,010 ) $ 29.79 Forfeited ( 40,675 ) $ 30.15 — $ — ( 40,675 ) $ 30.15 Nonvested, December 31, 2025 390,496 $ 30.80 — $ — 390,496 $ 30.80 The total aggregate grant date fair value of PSUs that vested during the years ended December 31, 2025, 2024, and 2023 were $ 4.8 million, $ 3.9 million, and $ 4.1 million, respectively. Total aggregate vest date fair value of PSUs that vested during the years ended December 31, 2025, 2024, and 2023 were $ 6.2 million, $ 4.0 million and $ 4.5 million, respectively. Performance-Based Awards The performance-based PSU awards require certain performance targets to be achieved in order to vest. Vesting is also subject to continued service requirements through the date the achievement of the performance target is certified. As of December 31, 2025, the total unrecognized compensation expense was $ 8.2 million. The Company expects to prospectively recognize these expenses over a weighted-average period of 1.7 years. Market-Based Awards The market-based PSU awards are subject to achievement of market-based performance targets in order to vest. The Company used a Monte-Carlo Simulation to determine the fair value and expected term of the awards as of grant date. The market-based performance target was achieved in the third quarter of 2025 and therefore the market-based PSU awards are fully vested as of December 31, 2025. There was no unrecognized compensation expense as of December 31, 2025. 142 11. Earnings (Loss) per Share Basic earnings (loss) per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock options, stock awards, and employee stock purchase plan (ESPP) awards using the treasury-stock method, and the 2023 Notes using the if-converted method. The following table sets forth the computation of basic and diluted EPS for the years ended December 31, 2025, 2024 and 2023 (dollars in thousands, except share and per share amounts): Year Ended December 31, 2025 2024 2023 Numerator: Net earnings (loss) $ ( 38,550 ) $ 73,865 $ 1,316 Numerator for basic and dilutive earnings per share $ ( 38,550 ) $ 73,865 $ 1,316 Denominator: Weighted average shares outstanding, basic 56,451,136 55,100,063 54,536,281 Effect of dilutive securities: Stock options and stock awards — 858,474 970,547 Weighted average shares outstanding, diluted 56,451,136 55,958,537 55,506,828 Earnings (loss) per share, basic $ ( 0.68 ) $ 1.34 $ 0.02 Earnings (loss) per share, diluted $ ( 0.68 ) $ 1.32 $ 0.02 Effect of Convertible Notes and Related Convertible Note Hedges and Warrants In connection with the issuance of the 2023 Notes, the Company entered into convertible note hedge and warrant transactions. The expected collective impact of the convertible note hedge and warrant transactions is to reduce the potential dilution that would occur if the price of the Company's common stock was between the conversion price of $ 59.33 per share and the strike price of the warrants of $ 80.91 per share. The convertible note hedge and warrant transactions were excluded in the calculation of diluted EPS because inclusion would be anti-dilutive. Specifically, the denominator of the diluted EPS calculation excludes the additional shares related to the warrants because the average price of the Company's common stock was less than the strike price of the warrants of $ 80.91 per share. Prior to actual conversion, the convertible note hedge transactions were not considered in calculating diluted EPS, as their impact would be anti-dilutive. In addition to the above described effect of the convertible note hedge and warrant transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards and shares associated with the conversion of the 2023 Notes in the calculation of diluted EPS, because their inclusion would be anti-dilutive: Year Ended December 31, 2025 2024 2023 Stock options and stock awards 7,130,198 601,684 543,140 2023 Notes — — 1,691,337 143 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 12. Income Tax Expense (Benefit) The tables below for the year ended December 31, 2025 provide the updated requirements of ASU 2023-09, which was adopted on a prospective basis. See Note 2, Summary of Significant Accounting Policies , for additional details on the adoption of ASU 2023-09. The components of income (loss) before income taxes for the year ended December 31, 2025, were attributable to the following regions (dollars in thousands): Year Ended December 31, 2025 Domestic $ ( 48,825 ) Foreign ( 205 ) Total income (loss) before income taxes $ ( 49,030 ) The summary of the income tax expense (benefit) for the year ended December 31, 2025 is as follows (dollars in thousands): Year Ended December 31, 2025 Current tax expense (benefit) Federal $ ( 10,622 ) State ( 5,064 ) Foreign — Total current tax expense (benefit) $ ( 15,686 ) Deferred tax expense (benefit) Federal $ 8,086 State ( 2,831 ) Foreign ( 49 ) Total deferred tax expense (benefit) $ 5,206 Income tax expense (benefit) — Federal $ ( 2,536 ) State ( 7,895 ) Foreign ( 49 ) Total income tax expense (benefit) $ ( 10,480 ) As previously disclosed for the years ended December 31, 2024 and December 31, 2023, prior to the adoption of ASU 2023-09, the summary of the income tax expense for the years ended December 31, 2024, and 2023 is as follows: 144 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Financial Statements (Continued) 12. Income Tax Expense (Benefit) (Continued) Year Ended December 31, 2024 2023 Current tax expense (benefit) Federal $ 31,217 $ 20,772 State 12,925 6,395 Deferred tax expense (benefit) Federal ( 18,920 ) ( 21,351 ) State ( 1,217 ) ( 4,363 ) Total income tax expense $ 24,005 $ 1,453 A reconciliation of income tax benefit at the U.S. federal statutory income tax rate for the year ended December 31, 2025, to annual income tax benefit at the Company's effective tax rate is as follows: Year Ended December 31, 2025 Amount Percent Income tax benefit computed at U.S. federal statutory income tax rate $ ( 10,296 ) 21.0 % State and local income taxes, net of federal income tax effect (1) ( 5,146 ) 10.5 % Domestic federal Tax credits Research and development credits ( 4,294 ) 8.8 % Change in valuation allowance ( 438 ) 0.9 % Nontaxable or nondeductible items Limitation on officers' compensation 2,401 ( 4.9 ) % Stock compensation ( 1,914 ) 3.9 % Meals and entertainment 831 ( 1.7 ) % Contingent consideration 5,338 ( 10.9 ) % Transaction costs 5,579 ( 11.4 ) % Other 154 ( 0.3 ) % Other ( 995 ) 2.0 % Changes in unrecognized tax benefits ( 1,695 ) 3.5 % Foreign tax effects ( 5 ) — % Income tax expense (benefit) and Effective tax rate $ ( 10,480 ) 21.4 % ______________________________ (1) In 2025, state and local income taxes in Maryland, Pennsylvania, Tennessee, and Indiana comprise the majority (greater than 50%) of the state and local income taxes category. The effective income tax rate for 2025 of 21.4 % varies from the statutory rate due to the favorable effect of state taxes and the research and development credit, which is offset by the effect of expenses related to current and prior year transactions that are not deductible for tax purposes. Included within transaction costs are payments to former employees of Sage which are not deductible for tax purposes. 145 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Financial Statements (Continued) 12. Income Tax Expense (Benefit) (Continued) As previously disclosed for the years ended December 31, 2024 and December 31, 2023, prior to adoption of ASU 2023-09, a reconciliation of income tax expense at the U.S. federal statutory income tax rate to annual income tax expense at the Company's effective tax rate is as follows (dollars in thousands): Year Ended December 31, 2024 2023 Income tax expense computed at U.S. federal statutory income tax rate $ 20,553 $ 581 State income taxes 5,114 ( 330 ) Permanent items 131 3,028 Research and development credits ( 8,628 ) ( 1,117 ) Loss on investment ( 2,147 ) — Uncertain income tax position 2,620 ( 2,529 ) Change in valuation allowance 5,859 1,267 Other 503 553 Income tax expense $ 24,005 $ 1,453 The amounts of income taxes paid, net of refunds received, consisted of the following (dollars in thousands): Year Ended December 31, 2025 Federal $ 9,000 State Illinois 940 Maryland ( 3,186 ) New Jersey 1,281 Pennsylvania 3,106 All other states 4,910 Total $ 16,051 In 2025, income taxes paid, net of refunds, exceeded 5% of total income taxes paid, net of refunds, in U.S. Federal jurisdiction, and Illinois, Maryland, New Jersey, and Pennsylvania state jurisdictions. 146 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Financial Statements (Continued) 12. Income Tax Expense (Benefit) (Continued) The significant components of the Company's deferred income tax assets (liabilities) are as follows (dollars in thousands): Year Ended December 31, 2025 2024 Deferred tax assets: Net operating loss carryforwards $ 571,102 $ 93,109 Accrued product returns and rebates 18,537 20,627 Accrued compensation and stock based compensation 15,478 15,912 Operating lease liability 10,198 8,608 Capitalized research and development 161,034 47,103 Other 13,729 14,100 Total deferred tax assets 790,078 199,459 Less: valuation allowance ( 590,223 ) ( 66,725 ) Total deferred tax asset, net of valuation allowance 199,855 132,734 Deferred tax liabilities: Intangibles ( 137,425 ) ( 128,188 ) Operating lease assets ( 6,659 ) ( 6,159 ) Other ( 17,420 ) ( 3,348 ) Total deferred tax liabilities ( 161,504 ) ( 137,695 ) Net deferred tax assets (liabilities) $ 38,351 $ ( 4,961 ) In assessing the realizability of deferred income tax assets, the Company considers whether it is more-likely-than-not that some or all of the deferred income tax assets will not be realized. The ultimate realization of the deferred income tax assets is dependent upon the generation of future taxable income during the periods in which the deferred tax assets are available. The Company considers projected future taxable income, the scheduled reversal of deferred income tax liabilities, and available tax planning strategies that can be implemented by the Company in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are available to reduce income taxes payable, management has determined it is not more likely than not the Company will realize certain deferred tax assets related to net operating losses and credit carryforwards. A reconciliation of the deferred tax asset valuation allowance is as follows (dollars in thousands): Year Ended December 31, 2025 2024 2023 Beginning balance $ 66,725 $ 60,866 $ 59,598 Acquisition Accounting (1) 587,432 — — Additions — 6,785 1,268 Reductions ( 63,934 ) ( 926 ) — Ending balance $ 590,223 $ 66,725 $ 60,866 (1) Amount comprised principally of acquisition and purchase accounting adjustments in connection with the Sage acquisition. The Company recorded a net valuation allowance addition of $ 523.5 million for the year ended December 31, 2025. The valuation allowance is primarily related to federal and state net operating loss carryforwards acquired from the Sage Acquisition that are not expected to be realized in the future. 147 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Financial Statements (Continued) 12. Income Tax Expense (Benefit) (Continued) The Company has net operating loss carryforwards in several jurisdictions. Due to changes in the Company's ownership, the utilization of net operating loss carryforwards that can be used to offset future taxable income are subject to annual limits in accordance with Internal Revenue Code provisions, as well as similar state provisions. In addition, states may also impose other future limitations through state legislation or similar measures. Despite the net operating loss carryforwards, the Company may incur higher state income tax expense in the future. As of December 31, 2025, the U.S. federal and state net operating loss carryforwards amounted to approximately $ 2.5 billion and $ 851.0 million, respectively. $ 2.4 billion and $ 90.5 million of the federal and state net operating losses will not expire. The remainder will expire in various years beginning in 2031. The Company is no longer subject to U.S. Federal income tax examinations for years prior to 2022 with the exception that operating loss or tax credit carryforwards generated prior to 2022 may be subject to tax audit adjustment. The Company accounts for uncertain income tax positions pursuant to the guidance in ASC Topic 740, Income Taxes . The Company recognizes interest and penalties related to uncertain tax positions, if any, in Income tax expense . Some uncertain income tax position liabilities have been recorded against the Company's deferred income tax assets to offset such tax attribute carryforwards. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (dollars in thousands): Year Ended December 31, 2025 2024 2023 Balance as of January 1 $ 5,840 $ 2,149 $ 4,323 Gross increases related to current year tax positions 9,370 517 112 Gross increases related to prior year tax positions 2,109 3,829 9 Gross decreases related to prior year tax positions ( 2,996 ) — — Lapse of statute of limitations ( 332 ) $ ( 655 ) ( 2,295 ) Balance as of December 31 $ 13,991 $ 5,840 $ 2,149 Unrecognized tax benefits included in Other liabilities in the consolidated balance sheet was $ 3.5 million, $ 1.7 million and $ 1.6 million as of December 31, 2025, December 31, 2024 and December 31, 2023, respectively . As of December 31, 2025, $ 5.1 million of our liabilities for unrecognized tax benefits would impact the effective tax rate, if recognized. As of December 31, 2024 and December 31, 2023, all of our liabilities for unrecognized tax benefits would impact the effective tax rate, if recognized. Interest and penalties recognized in the consolidated statement of earnings (loss) in 2025, 2024 and 2023, and accrued interest and penalties as of December 31, 2025 and 2024 was negligible. As of December 31, 2025, and 2024, the Company had an income tax receivable of $ 38.4 million and $ 5.0 million, respectively, which is classified as Prepaid expenses and other current assets on the consolidated balance sheets. 13 . Leases Office Space and Fleet Vehicle Leases The Company has operating leases for its headquarters lease, certain office space, certain office equipment and its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. The Company made an accounting policy election, by class of underlying asset, to combine the lease and non-lease components for the headquarters, office space, office equipment and fleet vehicle leases. 148 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Financial Statements (Continued) 13. Leases (Continued) The Company's headquarters lease commenced on February 1, 2019 (the Commencement Date) and will continue until April 30, 2034, unless terminated earlier in accordance with the terms of the lease. The lease includes options to extend the lease for up to ten years . As part of the Adamas Acquisition, the Company acquired a lease for office space. Adamas' operating lease for the office space term expired on April 30, 2025. Lease obtained from Sage Acquisition As part of the Sage Acquisition, the Company acquired a lease for office space in a multi-tenant building located in Cambridge, Massachusetts and classified this as an operating lease. Sage's office space lease term continues through February 28, 2030 unless terminated earlier in accordance with the terms of the lease. The lease includes an option to extend the lease for an additional five-year period. See Note 3 , Sage Acquisition , for the further discussion on the acquired lease asset and assumed lease liability. Contract Manufacturing Lease The Company has a contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz), for the manufacture and supply of rimabotulinumtoxinB finished products (Merz Agreement). The Merz Agreement will expire in July 2027 unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience. Under the terms of the original agreement, the Company was required to purchase a minimum quantity of MYOBLOC finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility which the Company accounted for as an embedded lease. In October 2021, the Company entered into an amendment to the Merz Agreement which increased the price of the annual purchase commitment of MYOBLOC from € 3.0 million to approximately € 3.9 million. A further amendment to the Merz Agreement was executed in July 2025, which included among other things, the removal of the annual minimum purchase requirement of MYOBLOC, and the Company's agreement to pay a nonrefundable annual fee of € 3.0 million to cover general maintenance and reservation costs for the manufacturing facilities. The Company made an accounting policy election, by class of underlying asset, to not combine lease and non-lease components for the manufacturing facility. A portion of the in-substance fixed contract consideration was allocated to the lease component based on the stand-alone selling price. Accordingly, the Company classified and accounted for the embedded lease as an operating lease. Operating lease assets and lease liabilities as reported on the consolidated balance sheets are as follows (dollars in thousands): Year Ended December 31, Balance Sheet Classification 2025 2024 Assets Operating lease assets Other assets $ 26,712 $ 24,477 Total lease assets $ 26,712 $ 24,477 Liabilities Lease liabilities, current Operating lease liabilities, current portion Accounts payable and accrued liabilities $ 10,612 $ 6,889 Lease liabilities, long-term Operating lease liabilities, long-term Operating lease liabilities, long-term 30,365 27,382 Total lease liabilities $ 40,977 $ 34,271 149 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Financial Statements (Continued) 13. Leases (Continued) The components of operating lease costs are as follows (dollars in thousands): Year Ended December 31, 2025 2024 2023 Operating lease cost: Fixed lease cost $ 9,914 $ 8,945 $ 8,258 Variable lease cost 5,816 5,475 5,998 Total $ 15,730 $ 14,420 $ 14,256 Supplemental cash flow information related to leases is as follows (dollars in thousands): Year Ended December 31, 2025 2024 2023 Cash paid for operating leases $ 18,484 $ 17,283 $ 17,112 Lease assets obtained for new operating leases (1) 10,215 3,662 7,170 ______________________________ (1) Includes right-of-use asset associated with the acquired Sage headquarters lease. Refer to Note 3, Sage Acquisition . The weighted average lease term and weighted average discount rate for operating leases are as follows: Year Ended December 31, 2025 2024 Weighted-average remaining lease term (years) 5.9 7.0 Weighted-average discount rate 5.3 % 4.9 % Future minimum lease payments under noncancellable operating leases as of December 31, 2025, are as follows (dollars in thousands): Operating Leases Year ending December 31: 2026 $ 12,413 2027 7,198 2028 6,547 2029 6,296 2030 3,666 Thereafter 10,878 Total future minimum lease payments 46,998 Less: Imputed interest (1) ( 6,021 ) Present value of lease liabilities $ 40,977 (1) Calculated using the interest rate for each lease. 14 . Segment Reporting The Company operates in one operating segment and therefore has only one reportable segment. The Company derives revenue primarily from sales of its commercial products in the U.S. The Company's chief operating decision maker (CODM) is the chief executive officer. The Company manages the business activities on a consolidated basis. The CODM assesses performance of the Company, and decides how to allocate resources based on net earnings (loss), which is reported in the consolidated statement of earnings (loss) as Net earnings (loss) 150 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 14 . Segment Reporting (Continued) and allocates resources on a consolidated basis. The CODM uses net earnings (loss) to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings (loss) is also used to monitor budget versus actual results. The measure of the reportable segment assets is reported on the balance sheet as total assets. The accounting policies of the reportable segment are the same as those described in Note 2, Summary of Significant Accounting Policies . The following table shows the segment revenue, significant segment expenses and net earnings (loss) (dollars in thousands): Year Ended December 31, 2025 2024 2023 Total revenues $ 718,952 $ 661,817 $ 607,521 Less: Significant Segment Expenses: Cost of revenues 74,562 77,906 83,779 Selling 209,695 153,105 149,955 Marketing 78,956 74,188 79,231 General and administrative (a) 123,987 94,289 107,175 Acquisition-related expenses (b) 72,925 — — Research and development expenses External development program expenses: ONAPGO 1,883 1,641 3,825 SPN-820 10,075 27,042 12,311 SPN-817 15,727 9,837 9,397 Qelbree 11,411 15,819 11,101 ZURZUVAE 2,145 — — Early-stage programs and other expenses 20,926 16,352 20,467 Total external development program expenses 62,167 70,691 57,101 Internal employee-related expenses 44,068 38,105 34,492 Total research and development expenses 106,235 108,796 91,593 Other segment items (c) 91,142 79,668 94,472 Net earnings (loss) $ ( 38,550 ) $ 73,865 $ 1,316 ______________________________ (a) Excludes Sage Acquisition expenses which are presented in the separate line item, Acquisition-related expenses, in the table above. (b) Sage Acquisition related expenses includes primarily transaction costs incurred, post-combination employee-related expenses incurred by the Company, share-based compensation expense for Sage incurred to accelerate the vesting of certain equity awards under the terms of the Merger Agreement, and share-based compensation expense for Sage equity awards that also had a CVR right (accounted for under employee compensation accounting model), which was deemed probable of achievement in the fourth quarter of 2025. (c) Other segment items include amortization of intangible assets, intangible asset impairment charges, contingent consideration loss (gain), net interest and other income, and income tax expense, whose amounts are disclosed in the consolidated statement of earnings (loss). 151 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 15. Collaboration Agreements Navitor See Note 5, Investments, for further details . Shionogi The Company is party to a collaboration and license agreement with Shionogi whereby Shionogi is responsible for all clinical development and regulatory filings for zuranolone in MDD and other indications in Japan, the Republic of Korea (South Korea), and Taiwan (together, the Shionogi Territory) and would be responsible for commercialization of zuranolone in the Shionogi Territory, if zuranolone is successfully developed and obtains marketing approval in any of the countries within the Shionogi Territory. Shionogi was required to make an upfront payment to Sage of $ 90.0 million (prior to our acquisition of Sage), and the Company is eligible to receive additional payments of up to $ 470.0 million if certain regulatory and commercial milestones are achieved by Shionogi. The potential future milestone payments include up to $ 40.0 million for the achievement of specified regulatory milestones, up to $ 30.0 million for the achievement of specified commercialization milestones, and up to $ 385.0 million for the achievement of specified net sales milestones. The Company is eligible to receive tiered royalties on sales of zuranolone in the Shionogi Territory, if development efforts are successful, with tiers averaging in the low to mid-twenty percent range, subject to other terms of the agreement. As between the Company and Shionogi, the Company maintains exclusive rights to develop and commercialize zuranolone outside of the Shionogi Territory. The upfront cash payment and any payments for milestones and royalties are non-refundable and non-creditable. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments from Shionogi. In the fourth quarter of 2025, Shionogi received approval from the Pharmaceuticals and Medical Devices Agency for the manufacturing and marketing of a product containing zuranolone in Japan for the treatment of MDD. As such, for the year ended December 31, 2025, the Company recognized $ 15.0 million of licensing revenue related to the achievement of a milestone under its collaboration agreement with Shionogi. No product containing zuranolone is approved for the treatment of MDD in the United States. Under the clinical supply agreement, the Company is obligated to manufacture and supply to Shionogi (i) clinical quantities of API reasonably required by Shionogi for the development of licensed products in the Shionogi Territory under the collaboration and license agreement and (ii) quantities of drug product reasonably required for use by Shionogi in Phase 1 clinical trials of zuranolone in the Shionogi Territory under the collaboration and license agreement, in the quantities agreed to by the parties. A commercial supply agreement has not yet been entered into and the parties are operating under the provisions of the existing clinical supply agreement. Biogen Under the terms of the Biogen Collaboration Agreement, the Company granted Biogen a co-exclusive license to develop and commercialize SAGE-217 products in the U.S., an exclusive license to develop and commercialize SAGE-217 products in all countries of the world other than the U.S. and the Shionogi Territory. The Company refers to the territories outside the U.S. to which Biogen has rights under the Biogen Collaboration Agreement with respect to SAGE-217 as the Biogen Territory. Development and commercialization activities in the U.S. under the Biogen Collaboration Agreement are conducted pursuant to plans agreed to by the Company and Biogen and overseen by a joint steering committee that consists of an equal number of representatives of each party. The Company and Biogen share equally in the costs for development and commercialization, as well as the profits and losses upon FDA approval and commencement of product sales, in the U.S., subject to the Company’s opt-out right described below. Biogen is solely responsible for all development activities and costs related to any development and commercialization of SAGE-217 products for the Biogen Territory, and the Company will receive royalties on any sales in the Biogen Territory, as mentioned above. Biogen is the principal and records sales of SAGE-217 products globally. The Company is obligated to supply API and bulk drug product for the Biogen Territory and API, bulk drug product and final drug product for the U.S. to support development and commercialization activities. Biogen has the right to assume manufacturing responsibilities for API for the Biogen Territory at any time during the term of the Biogen Collaboration 152 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 15. Collaboration Agreements (Continued) Agreement, and the Biogen Collaboration Agreement further provides that Biogen will, within a reasonable period of time, assume manufacturing responsibility for bulk drug product for the Biogen Territory. Unless terminated earlier, the Biogen Collaboration Agreement will continue on a country-by-country basis until the date on which (a) in any country in the Biogen Territory, the royalty term has expired in such country, and (b) for the U.S., the parties agree to permanently cease to commercialize. Biogen also has the right to terminate the Biogen Collaboration Agreement for convenience in its entirety or as to a particular region, upon advance written notice. The Company has an opt-out right to convert the co-exclusive license in the U.S. to an exclusive license to Biogen. Following the exercise of the opt-out right, the Company would no longer share equally in the profits and losses in the U.S. and would be entitled to receive certain royalty payments at percentage rates ranging from the low to high twenties and additional sales milestones. While Biogen is considered the principal in transactions with customers for the sale of ZURZUVAE globally, the Company is also engaged in significant commercialization activities, including maintaining its own U.S. direct sales force. The Company presents its proportionate share of Biogen’s ZURZUVAE sales to customers in the U.S. as Collaboration revenue (ZURZUVAE) within the consolidated statements of earnings (loss) . Payments to or reimbursements from Biogen related to the agreement of the parties to share equally in all revenues and costs are accounted for as an increase to Collaboration revenue (ZURZUVAE) , an increase to or reduction of Cost of revenues , Research and development expenses , or Selling, general and administrative expenses , in the consolidated statements of earnings (loss), depending on the nature of the activity. To record its proportionate share of collaboration revenue from Biogen’s sales of ZURZUVAE to customers in the U.S., the Company utilizes certain information from Biogen, including revenue from the sale of the product and associated reserves on revenue. The following table summarizes the Company’s proportionate share of the activity under the Biogen Collaboration Agreement: Year ended December 31, 2025 Collaboration revenue (ZURZUVAE) $ 52,996 Cost of revenues 1,497 Research and development expenses ( 751 ) Selling, general and administrative expenses 35,657 Amounts receivable from Biogen related to the Biogen Collaboration Agreement are recorded within Accounts receivable, net on the consolidated balance sheets and were $ 23.0 million as of December 31, 2025. There were no amounts receivable from Biogen as of December 31, 2024. 16. Composition of Other Balance Sheet Items The following details the composition of other balance sheet items (dollars in thousands for amounts in tables): Accounts Receivable, Net As of December 31, 2025 and December 31, 2024, the Company recorded allowances of approximately $ 13.5 million and $ 12.3 million, respectively, for prompt pay discount and contractual service fees paid to the Company's customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies. The Company accounts for these prompt pay discount and contractual service fees as reduction to gross product sales at the time of sale. See Note 2, Summary of Significant Accounting Policies - Revenue from Product Sales. 153 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 16. Composition of Other Balance Sheet Items (Continued) Inventories, net Inventories consist of the following (dollars in thousands): December 31, 2025 December 31, 2024 Raw materials $ 31,833 $ 11,127 Work in process 29,436 26,725 Finished goods 21,116 16,441 Total $ 82,385 $ 54,293 The Company recorded inventory write-offs of $ 1.9 million, $ 8.9 million and $ 8.0 million for the years ended December 31, 2025, 2024 and 2023, respectively. The inventory write-offs are reported on the consolidated statement of earnings (loss) in Cost of revenues . Inventories, net as reported on the consolidated balance sheets are as follows (dollars in thousands): Balance Sheet Classification December 31, 2025 December 31, 2024 Current inventory Inventories, net $ 82,385 $ 54,293 Noncurrent inventory Other assets 30,095 — Total $ 112,480 $ 54,293 Property and Equipment, net Property and equipment consist of the following (dollars in thousands): December 31, 2025 December 31, 2024 Lab equipment and furniture $ 14,041 $ 13,370 Leasehold improvements 13,052 14,023 Software 871 883 Computer equipment 831 1,112 28,795 29,388 Less accumulated depreciation and amortization ( 18,264 ) ( 17,843 ) Total $ 10,531 $ 11,545 Depreciation and amortization expense on property and equipment was approximately $ 2.1 million, $ 2.4 million, and $ 2.5 million for the years ended December 31, 2025, 2024 and 2023, respectively. 154 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 16. Composition of Other Balance Sheet Items (Continued) Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consist of the following (dollars in thousands): December 31, 2025 December 31, 2024 Accrued compensation, benefits, & related accruals 29,446 21,225 Accrued manufacturing expenses 25,608 11,652 Accrued sales & marketing 16,665 11,007 Other accrued expenses 13,090 6,989 Operating lease liabilities, current portion (1) 10,612 6,889 Accrued R&D expenses 7,299 5,898 Accounts payable 2,677 4,587 Accrued royalties (2) 2,403 8,105 Total $ 107,800 $ 76,352 (1) Refer to Note 13 , Leases . (2) Refer to Note 18 , Commitments and Contingencies . Accrued Product Returns and Rebates Accrued product returns and rebates consist of the following (dollars in thousands): December 31, 2025 December 31, 2024 Accrued product rebates $ 123,297 $ 115,330 Accrued product returns 37,800 53,375 Total $ 161,097 $ 168,705 17. Interest Expense Interest expense consists of the following (dollars in thousands): Year Ended December 31, 2025 2024 2023 Interest expense $ — $ — $ ( 1,321 ) Interest expense on nonrecourse liability related to sale of future royalties — — ( 562 ) Noncash interest expense on debt — — ( 532 ) Total $ — $ — $ ( 2,415 ) Noncash interest expense on debt is related to amortization of deferred financing costs on the 2023 Notes. The Company fully amortized the deferred financing costs on the 2023 Notes in the first quarter of 2023. (see Note 9, Debt ). 18. Commitments and Contingencies Product Licenses The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement. 155 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 18. Commitments and Contingencies (Continued) Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, ONAPGO, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of revenues in the consolidated statements of earnings (loss). Through the Sage Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for ZURZUVAE (zuranolone). See Note 2, Summary of Significant Accounting Policies - Revenue Recognition - Collaborative Arrangements and Note 15, Collaboration Agreements for further details. USWM Enterprises Commitments Assumed As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below. The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated € 3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply. An amendment to the contract manufacturing agreement with Merz was executed in July 2025. Amendments to the contract manufacturing agreement included among other things, the removal of the annual minimum purchase requirement of MYOBLOC, and the Company's agreement to pay a nonrefundable annual fee of € 3.0 million to cover general maintenance and reservation costs for the manufacturing facilities. MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services which was effective in April 2019. Under the CIA, the MDD Subsidiaries agreed to and paid $ 17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company continues to maintain a broad array of processes, policies and procedures necessary to comply with the CIA and submitted its final report during the second quarter of 2024. The Company received an official notification of release from the Office of the Inspector General in April 2025 and thus no longer remains subject to its obligations under the CIA. Claims and Litigation From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on its financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows. NAMENDA XR/Namzaric Qui Tam Litigation On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic 156 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 18. Commitments and Contingencies (Continued) manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $ 2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit which was denied on November 3, 2022. On December 23, 2022, the defendants filed renewed motions to dismiss directed to the remaining unresolved issue. On March 20, 2023, the District Court entered an order and final judgment dismissing with prejudice the FCA claim while declining to exercise supplemental jurisdiction over the state false claims act claims which were dismissed without prejudice. On April 19, 2023, the plaintiff appealed the District Court's dismissal of the Federal False Claims Act claim. On February 20, 2024, the plaintiff filed a motion for an indicative ruling and to set aside the judgment in the District Court, based on the same arguments raised in his appeal. That motion was fully briefed and the District Court determined that the motion for an indicative ruling was suitable for determination without a hearing. On May 7, 2024, the District Court denied the plaintiff’s motion for an indicative ruling. The appeal is fully briefed, and the Ninth Circuit heard oral argument on November 21, 2024. On January 29, 2025, the Ninth Circuit affirmed the District Court’s order dismissing the litigation. On March 31, 2025, the plaintiff filed a petition for rehearing by the Ninth Circuit, but the Ninth Circuit denied the Petition on April 15, 2025. The plaintiff opted not to seek review from the U.S. Supreme Court. It remains to be seen whether he will attempt to refile any of his state-law FCA claims. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation. APOKYN Litigation On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited (Britannia), and US WorldMeds Partners, LLC (US WorldMeds) violated state and federal antitrust law in connection with APOKYN® (apomorphine HCl). On October 16, 2022, Plaintiffs amended their complaint to add additional defendants MDD US Enterprises, LLC, MDD US Operations, LLC (each a subsidiary of Supernus Pharmaceuticals, Inc.), USWM, LLC (USWM), and individual defendants Paul Breckinridge Jones, Sr., Herbert Lee Warren, Jr., Henry Van Den Berg, and Kristin L. Gullo. On January 10, 2023, Defendants filed an Omnibus Motion to Dismiss the Amended Complaint seeking dismissal of each of Plaintiffs’ claims and the lawsuit in its entirety and US WorldMeds with USWM, Britannia, and the group of individual defendants each filed separate motions to dismiss. On May 9, 2024, and May 28, 2024, respectively, the Court denied the Defendants’ omnibus motion and the Britannia motion to dismiss. On May 31, 2024, and June 4, 2024, respectively, the Court granted the individual defendants’ motion to dismiss and the US WorldMeds and USWM motion to dismiss. On December 6, 2024, Plaintiffs filed a second amended complaint, which added US WorldMeds and USWM back to the case. The Court ordered on February 3, 2026, that case dispositive and Daubert motions briefing would begin on June 9, 2026, with a hearing scheduled for September 18, 2026, pretrial conference set for January 15, 2027, and trial beginning January 25, 2027. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation. Sage Legal Proceedings Merger Complaints In connection with the Merger Agreement and Sage's Board of Directors' (Sage Board) recommendation to Sage shareholders to tender their shares pursuant to the tender offer, two purported Sage shareholders filed complaints in state court against Sage and each member of the Sage Board. Among other things, the complaints assert claims for negligent misrepresentation and concealment and negligence under New York common law. Sage has also received certain demand letters from other purported shareholders with similar allegations to those contained in the complaints. Additional demand letters may be received by Sage and additional complaints may be filed against Sage, the Sage Board, Supernus and Saphire, Inc. in connection with the Merger Agreement and tender offer. 157 Table of Contents Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements (Continued) 18. Commitments and Contingencies (Continued) Securities Class Action On August 28, 2024, named plaintiff Darren Korver filed a purported federal securities class action lawsuit in the Southern District of New York against Sage and individuals, Barry E. Greene and Kimi Iguchi (Securities Class Action). The complaint in the Securities Class Action alleges violations of U.S. securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and seeks an as-yet unspecified amount of damages allegedly sustained by parties who purchased Sage stock between April 12, 2021 and July 23, 2024, as well as applicable attorneys’ fees and costs. Sage denies any allegations of wrongdoing and intends to vigorously defend against the Securities Class Action. U.S. Securities and Exchange Commission (SEC) Investigation On October 16, 2024, Sage received a subpoena from the Enforcement Division of the SEC requesting documents and information related to Sage’s NDA for zuranolone for the treatment of major depressive disorder (MDD), including communications with the FDA and any communications containing material nonpublic information. The Company is cooperating with the SEC and intends to continue to provide information responsive to the SEC’s requests. Consolidated Derivative Litigations On March 26, 2025, plaintiff shareholder Qingping Zhu commenced derivative litigation in the Southern District of New York, purportedly on behalf of Sage, against sixteen current and former officers and directors of Sage (the Zhu Derivative Litigation). Based significantly on the allegations underlying the Securities Class Action, the Zhu Derivative Litigation alleges violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder, breaches of fiduciary duty, unjust enrichment, and waste of corporate assets, and seeks unspecified damages and various equitable relief. On April 14, 2025, the Southern District of New York granted a stay of the Zhu Derivative Litigation pending the resolution of the motion to dismiss the amended complaint in the Securities Class Action. On May 13, 2025, plaintiff shareholder Jurgen Matton commenced derivative litigation in the Southern District of New York, purportedly on behalf of Sage Therapeutics, against sixteen current and former officers and directors of Sage Therapeutics (the Matton Derivative Litigation). Based significantly on the allegations underlying the Securities Class Action, the Matton Derivative Litigation alleges violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder, breaches of fiduciary duty, unjust enrichment, and waste of corporate assets, and seeks unspecified damages and various equitable relief. On May 22, 2025, plaintiff shareholder Joseph Pizzelanti commenced derivative litigation in the Southern District of New York, purportedly on behalf of Sage Therapeutics, against sixteen current and former officers and directors of the Company (the Pizzelanti Derivative Litigation). Based significantly on the allegations underlying the Securities Class Action, the Pizzelanti Derivative Litigation alleges violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder, breaches of fiduciary duty, unjust enrichment, and waste of corporate assets, and seeks unspecified damages and various equitable relief. On June 20, 2025, Sage, along with other relevant parties, submitted for the Southern District of New York’s approval of a consolidation of the Zhu Derivative Litigation with the Matton Derivative Litigation and the Pizzelanti Derivative Litigation and the court approved such consolidation (the Consolidated Derivative Litigation). At this time, the Company is unable to predict the outcome of the Merger Complaints, Securities Class Action, the SEC investigation, or the Consolidated Derivative Litigation, or reasonably estimate a range of possible losses. The outcome of the matters described above cannot be predicted with certainty. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation. 19. Subsequent Event On January 22, 2026, the Company entered into a First Amendment (Amendment) to the Agreement and Plan of Merger dated September 12, 2018, with former Biscayne security holders. The Amendment relates to the timing and payment of certain milestones under the Biscayne merger agreement. The Company agreed to pay former Biscayne security holders $ 10.0 million by June 30, 2026. 158 Table of Contents ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. None.